SNARE mimicry by the CD225 domain of IFITM3 enables regulation of homotypic late endosome fusion

Kazi Rahman[1,#], Isaiah Wilt[1], Abigail A. Jolley[1], Bhabadeb Chowdhury[1], Siddhartha A. K. Datta[1], Alex A. Compton[1,*]

[1]HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland

[#]Present address: Department of Biochemistry and Microbiology, School of Health and Life Sciences, North South University, Dhaka, Bangladesh

[*]Corresponding author: alex.compton@nih.gov

Abstract

The CD225/Dispanins superfamily consists of membrane proteins that regulate vesicular transport and membrane fusion events driving neurotransmission, glucose transport, and antiviral immunity. However, how the CD225 domain controls membrane trafficking was unknown. We reveal that the CD225 domain contains a SNARE-like motif that enables interaction with cellular SNARE fusogens. Proline rich transmembrane protein 2 (PRRT2) encodes a SNARE-like motif that enables interaction with neuronal SNARE proteins, and mutations therein disrupt SNARE binding and are linked to neurological disease. Another CD225 member, interferon-induced transmembrane protein 3 (IFITM3), protects cells against Influenza A virus infection. IFITM3 interacts with SNARE proteins that mediate late endosome-late endosome (homotypic) fusion and late endosome-lysosome (heterotypic) fusion. IFITM3 binds to syntaxin 7 (STX7) in cells and in vitro, and mutations that abrogate STX7 binding cause loss of antiviral activity against Influenza A virus. Mechanistically, IFITM3 disrupts assembly of the SNARE complex controlling homotypic fusion and accelerates the trafficking of endosomal cargo to lysosomes. Our results suggest that SNARE modulation plays a previously unrecognized role in the diverse functions performed by CD225 proteins.

Introduction

Membrane fusion is a critical process enabling cargo transfer between membrane-bound compartments. The soluble NSF attachment protein receptor (SNARE) proteins are key mediators of membrane fusion and are involved in nearly every vesicular trafficking event in eukaryotic cells (Hong, 2005; Jahn & Scheller, 2006). SNARE proteins contain a so-called SNARE motif consisting of heptad repeats of generally hydrophobic amino acids surrounding a central hydrophilic residue (R for arginine or Q for glutamine) (Fasshauer *et al*, 1998). The central residue is referred to as the "0" layer while the hydrophobic residues surrounding it are numbered relative to the "0" layer, from "-7" to "+8" (**Figure 1A**). These features enable the assembly of four parallel alpha-helices (one R-SNARE motif and three Q-SNARE motifs) into a coiled-coil trans-SNARE complex across two membranes. Progressive folding of the bundle towards a cis-SNARE complex, in which the SNARE proteins reside within the same membrane, drives membrane fusion (Han *et al*, 2017). Humans encode a minimum of 38 SNARE proteins

which interact selectively to impart specificity and directionality to membrane fusion events
between different organelles (Kloepper *et al*, 2007).

Among the best studied are the synaptic SNARE proteins that mediate the exocytosis of
neurotransmitters from neurons (Sudhof, 2004). Neurotransmitter release at neuronal synapses
requires the fusion of synaptic vesicles with the presynaptic plasma membrane, and this requires
the assembly of syntaxin 1A and SNAP-25 (in the presynaptic plasma membrane) with VAMP2
(in the synaptic vesicle membrane) (Sutton *et al*, 1998; Xiao *et al*, 2001). The study of
neurological diseases associated with impaired neurotransmission has led to the identification of
cellular proteins that regulate synaptic SNARE assembly, such as proline-rich transmembrane
protein 2 (PRRT2) (Ebrahimi-Fakhari *et al*, 2015). Mutations in PRRT2 associated with a range
of neurological disorders in humans (including paraoxysmal kinesigenic dyskinia (PKD),
infantile epilepsy and convulsions, hemiplagic migraines, ataxia, and intellectual disability)
indicated that PRRT2 plays important roles in neurotransmission (Ebrahimi-Fakhari *et al.*, 2015).
Subsequently, it was shown that PRRT2 interacts with Q-SNAREs syntaxin 1A and SNAP-25
and disfavors their interaction with the R-SNARE VAMP2, thereby reducing synaptic SNARE
assembly and neurotransmitter release (Coleman *et al*, 2018; Ma *et al*, 2018; Tan *et al*, 2018;
Valente *et al*, 2016). However, a comprehensive understanding of the protein-protein interface
enabling this regulatory function of PRRT2 was unknown. PRRT2 belongs to the CD225
superfamily, a group that includes trafficking regulator of GLUT4 (TRARG1/TUSC5) and
interferon-induced transmembrane protein 3 (IFITM3) (Coomer *et al*, 2021). TUSC5 and
IFITM3 regulate vesicular trafficking during glucose transport and virus infection, respectively,
through incompletely understood mechanisms. IFITM3 provides constitutive and interferon-
induced protection of cells from endocytic viruses such as Influenza A virus (IAV) by homing to
virus-containing endosomes and inhibiting virus-cell membrane fusion, effectively preventing
the delivery of the viral core into host cell cytosol (where virus replication begins) (Desai *et al*,
2014; Klein *et al*, 2023; Li *et al*, 2013; Suddala *et al*, 2019). Moreover, *Ifitm3* knockout mice and
disease-associated single-nucleotide polymorphisms in human *IFITM3* revealed that IFITM3
prevents severe viral disease sequelae in vivo (Bailey *et al*, 2012; Everitt *et al*, 2012).

Here, we report the identification of an R-SNARE-like motif shared among many CD225
family members that enables SNARE binding and modulation of SNARE assemblies. Mutation
of residues within the R-SNARE-like motif of PRRT2, TUSC5, and IFITM3 resulted in reduced
Q-SNARE binding and loss of their respective functions, as demonstrated experimentally or by
associations with human disease. In-depth analysis revealed that IFITM3 interacts with
endosomal SNARE proteins and, as a result, inhibits the assembly of the SNARE complex
mediating homotypic late endosome fusion. Our findings suggest that cells expressing IFITM3
prioritize the heterotypic fusion pathway whereby late endosomes fuse with lysosomes, resulting
in endosomal cargo degradation. Our findings demonstrate that CD225 proteins regulate diverse
membrane trafficking processes in different tissues by regulating cellular fusion machinery via a
conserved R-SNARE-like motif.
86
87 **Results**
88
89 To investigate whether the known SNARE-binding activity exhibited by human PRRT2
90 may be attributed to the presence of a previously unrecognized SNARE-like motif, we performed
91 multiple protein sequence alignment between PRRT2 and a panel of Q- and R-SNARE proteins.
92 We found that PRRT2 encodes an arginine that aligns with the central arginines present within

canonical R-SNARE motifs, which are approximately 53 amino acids in length (**Figure 1A**). Furthermore, like canonical R-SNARE proteins, PRRT2 contains regularly spaced, generally hydrophobic residues extending on both sides of the central arginine. Therefore, PRRT2 contains a putative R-SNARE motif, resembling that which is present in VAMP proteins. Importantly, we also found this R-SNARE-like motif in additional members of the human CD225 protein family, including IFITM1, IFITM2, IFITM3, IFITM5, IFITM10, TUSC5, although the identity and number of hydrophobic layers surrounding the central arginine varied between members (**Figure 1**). The central arginine was lacking in a subset of CD225 family members (**Figure EV1A**), suggesting either that the R-SNARE-like motif does not trace its origins to the CD225 ancestor or that the motif was lost to decay in certain family members.

Next, since PRRT2 has been described to regulate the SNARE complex controlling neurotransmission (Coleman *et al.*, 2018), we measured whether the R-SNARE-like motif present within PRRT2 confers it with the ability to bind neuronal SNARE proteins. In agreement with previous reports, ectopic PRRT2 co-immunoprecipitated with ectopic Q-SNARE SNAP-25 (**Figure 1B**). Attesting to a critical role played by the R-SNARE-like motif of PRRT2 in mediating this interaction, mutation of the central arginine (R295Q) resulted in decreased co-immunoprecipitation between PRRT2 and SNAP-25 (**Figure 1B**). Furthermore, mutation of one of the hydrophobic layers of the R-SNARE-like motif of PRRT2 (A320V) also abrogated the interaction with SNAP-25, and a G305W mutation that is adjacent to a hydrophobic layer and which inhibits PRRT2 homodimerization (Rahman *et al*, 2020) also abrogated this interaction (**Figure 1B**). Meanwhile, these mutations in PRRT2 did not affect the interaction between PRRT2 and another Q-SNARE in the neuronal SNARE complex, syntaxin 1A (**Figure EV1B**). Importantly, all three mutations (R295Q, G305W, and A320V) in PRRT2 occur naturally as polymorphisms in humans and are linked to neurological dysfunction (Becker *et al*, 2013; Ma *et al.*, 2018; Tan *et al.*, 2018). Therefore, our results describing an R-SNARE-like motif in human PRRT2 provide a mechanistic basis for the previously described molecular interaction between PRRT2 and neuronal SNARE proteins, as well as an explanation for how R295Q, G305W, and A320V cause loss of PRRT2 function in vivo and neurological dysfunction.

TUSC5 is a CD225 family member expressed in adipose tissue and implicated in the translocation of glucose transporter type 4 (GLUT4) to the cell surface, a process essential for insulin-stimulated glucose transport (St-Denis & Cushman, 1998; Stöckli *et al*, 2011). It was previously reported that TUSC5 co-immunoprecipitated with GLUT4 and SNARE proteins implicated in the vesicular trafficking of GLUT4 (Beaton *et al*, 2015; Fazakerley *et al*, 2015). However, the basis for this interaction was unknown. Like the CD225 family member PRRT2, TUSC5 also encodes a putative R-SNARE-like motif (**Figure 1A**). Accordingly, we found that ectopic TUSC5 co-immunoprecipitated with ectopic syntaxin 4, a Q-SNARE involved in GLUT4 translocation, while a G141W mutation in TUSC5 (analogous to G305W in PRRT2) disrupted this interaction (**Figure EV1C**). Reverse co-immunoprecipitation confirmed this finding (**Figure EV1D**). Collectively, these results highlight the presence of a R-SNARE-like motif in CD225 family members that enables coordination of SNARE proteins involved in diverse membrane fusion processes.

The IFITM proteins IFITM1, IFITM2, and IFITM3 are among the best characterized members of the CD225 protein family due to their established roles in cell-intrinsic defense against diverse pathogenic viruses (Majdoul & Compton, 2021; Shi *et al*, 2017). IFITM2 arose through gene duplication of IFITM3 in the ancestor of great apes, and both IFITM2 and IFITM3 proteins accumulate in membranes of the endolysosomal compartment (Compton *et al*, 2016). In

addition to preventing virus escape from the endocytic compartment, it has been demonstrated
that IFITM3 redirects incoming virions to lysosomes for degradation (Feeley *et al*, 2011; Spence
et al, 2018; Suddala *et al.*, 2019). However, the mechanism for this latter effect by IFITM3 was
unknown, as was its relevance to the antiviral activity exhibited by IFITM3. Since IFITM3 is an
endolysosomal protein, we assessed whether the R-SNARE-like motif in IFITM3 (**Figure 1A**)
conferred IFITM3 with the ability to bind and regulate endolysosomal SNARE proteins.
Fusion between compartments of the endolysosomal system are controlled by SNARE
complexes consisting of the Q-SNAREs syntaxin 7 (STX7), syntaxin 8 (STX8), Vti1b, and one
of two R-SNAREs—VAMP8 or VAMP7 (**Figure 2A**). The STX7-STX8-Vti1b-VAMP8 complex
enables late endosome-late endosome (homotypic) fusion while the STX7-STX8-Vti1b-VAMP7
complex is responsible for late endosome-lysosome (heterotypic) fusion (Advani *et al*, 1999;
Mullock *et al*, 2000; Prekeris *et al*, 1999; Pryor *et al*, 2004). Endocytic viruses like IAV exploit
the endolysosomal network and the SNARE machinery found therein in order to avoid lysosomal
degradation and gain access to host cell cytosol, where virus replication is initiated. VAMP8 and
its role in late endosome homotypic fusion was previously reported to promote IAV entry into
cells. In contrast, VAMP7 inhibited IAV entry, presumably by favoring the degradation of virus-
laden late endosomes with lysosomes (Pirooz *et al*, 2014a; Pirooz *et al*, 2014b). Therefore, we
tested whether IFITM3 and the R-SNARE-like motif found in its CD225 domain could influence
the assembly of SNARE complexes regulating the endolysosomal network.
The R-SNARE-like motif is conserved among the interferon-inducible members of the
human IFITM family that exhibit antiviral activity—IFITM1, IFITM2, and IFITM3 (**Figure 2A**).
In contrast to a canonical R-SNARE protein like VAMP8, the R-SNARE-like motif of IFITM1-3
lack two layers of hydrophobicity at the amino-terminal end of the motif. Instead, IFITM1-3
encode an amphipathic helix that was shown to mediate cholesterol binding activity, membrane
binding, and which is essential for antiviral activity against IAV (Chesarino *et al*, 2017; Guo *et
al*, 2021; Rahman *et al.*, 2020; Rahman *et al*, 2022) (**Figure 2A**). Interestingly, the intact
hydrophobic layers forming part of the R-SNARE-like motif downstream of the amphipathic
helix include residues that were previously shown to be important for antiviral activity: a
cysteine residue previously shown to be palmitoylated (Chesarino *et al*, 2014; Hach *et al*, 2013;
Yount *et al*, 2010) and two phenylalanine residues shown to be critical for antiviral function(John
et al, 2013; Suddala *et al.*, 2019) (**Figure 2A**). Therefore, to provide further evidence that the R-
SNARE-like motif of IFITM3 contributes functionally to its antiviral activity, we assessed how
mutation of the central arginine (R85Q) or the two phenylalanines (F75A/F78A) impacted
antiviral activity against IAV. We also tested the effect of mutating glycine 95 (G95L), since it is
adjacent to a hydrophobic layer in the R-SNARE-like motif of IFITM3, is homologous to
glycine 305 in PRRT2 and glycine 141 in TUSC5 (**Figure 1B and Figure EV1C and EV1D**),
and was previously shown by us to be critical for antiviral activity (Rahman *et al.*, 2020). While
IFITM3 WT reduced IAV infection by approximately 80% relative to Empty Vector, all mutants
tested exhibited a near-total loss of antiviral activity (**Figure 2B**). These results indicate that the
antiviral activity of IFITM3 against IAV depends upon a previously uncharacterized R-SNARE-
like motif. Furthermore, our findings suggest that interactions with SNARE machinery may
comprise an essential but unrecognized component of IFITM3 function in cells.
Next, we addressed whether the R-SNARE-like motif of IFITM3 adopts a protein fold
resembling that of a genuine R-SNARE. Since the atomic structure of IFITM3 is incompletely
understood (Ling *et al*, 2016) and the influence of interaction partners on its structure has not
been explored, we used the TM-align platform (Zhang & Skolnick, 2005) to perform protein

structure alignment between the R-SNARE-like motif of IFITM3 and the R-SNARE motif of
VAMP8. The results supported that IFITM3 and VAMP8 adopt a highly similar alpha helical fold
in the region spanning their respective R-SNARE motifs (TM-score = 0.76) (**Figure EV2A**). To
further investigate the SNARE-like structural qualities of IFITM3, we used Alphafold (Mirdita *et*
al, 2022; Varadi *et al*, 2024) and the flexible protein structure alignment algorithm FATCAT (Li
et al, 2020) to model the R-SNARE-like motif of IFITM3 against a template consisting of the R-
SNARE motif of VAMP8, which was previously crystallized in the context of the STX8-STX7-
Vti1b-VAMP8 complex (Antonin *et al*, 2002). We found that the Alphafold model for the R-
SNARE-like motif of IFITM3 exhibited a high degree of structural homology with the R-
SNARE motif of VAMP8 (**Figure 2C**). We also swapped VAMP8 for IFITM3 in the context of
the STX7-STX8-Vti1b-VAMP8 complex to provide spatial orientation of the F75, F78, and R85
residues of IFITM3. We found that the side chains of F75, F78, and R85 are predicted to radiate
towards the center of the coiled-coil structure formed by Q-SNAREs STX7, STX8, and Vti1b
(**Figure EV2B**). Moreover, the central arginine (R85) of IFITM3 is predicted to align with the
central glutamine (Q) residues of STX7, STX8, and Vti1b (**Figure EV2C**). Therefore, IFITM3
encodes an R-SNARE-like motif that is predicted to behave like an endosomal R-SNARE
protein.
To determine whether the R-SNARE-like motif of IFITM3 confers it with the ability to
bind endolysosomal SNARE proteins in cells, we overexpressed IFITM3 in combination with
individual endolysosomal SNARE proteins in HEK293T cells and performed co-
immunoprecipitation. We found that IFITM3 immunoprecipitated from transfected cells pulled
down relatively high quantities of ectopic STX7, while other endolysosomal SNARE proteins
were pulled down to a lesser, or negligible, extent (**Figure 2D**). This selective co-
immunoprecipitation between IFITM3 and STX7 was not due to elevated STX7 levels in
transfected cells (**Figure 2D**). Importantly, mutations in IFITM3 that caused loss of antiviral
function (F75/78A, R85Q, and G95L) (**Figure 2B**) diminished binding with STX7 relative to
WT (**Figure 2E**). IFITM3 F75/78A and R85Q exhibited somewhat decreased steady-state levels
relative to WT, possibly attesting to the importance of the R-SNARE-like motif in maintaining
proper folding and stability of the IFITM3 polypeptide (**Figure 2E**). The association between
IFITM3 and STX7 was confirmed by reverse co-immunoprecipitation, whereby
immunoprecipitated ectopic STX7 pulled down ectopic IFITM3 (**Figure 3A**). Ectopic STX8 also
co-immunoprecipitated with IFITM3 but to a lesser extent than STX7 (**Figure 3A**). To further
support an association between IFITM3 and STX7, we performed confocal immunofluorescence
in intact cells transfected with ectopic IFITM3 and STX7-GFP. We observed colocalization
between IFITM3 WT and STX7-GFP, while IFITM3 G95L exhibited decreased colocalization
(**Figure 3B**). These results demonstrate that an R-SNARE-like motif in IFITM3 enables it to
bind to endosomal SNARE proteins, particularly Q-SNAREs STX7 and STX8. Furthermore,
there exists a functional requirement for the R-SNARE-like motif of IFITM3 during restriction
of IAV infection.
While our results are suggestive of selective binding between IFITM3 and Q-SNAREs
STX7 and STX8, we also detected pull down of VAMP8-HA when IFITM3 was
immunoprecipitated (**Figure 2D**). To confirm this interaction, we performed the reverse co-
immunoprecipitation and found that VAMP8-HA pulled down IFITM3 WT, while pulldown was
reduced by the G95L mutation (**Figure EV3A**). We also immunoprecipitated VAMP7-Myc and
assessed pull down of ectopic IFITM3, because a previously published proteomic dataset
identified VAMP7 as a possible binding partner of IFITM3 (Li *et al*, 2024). As was observed for

VAMP8-HA, VAMP7-Myc pulled down IFITM3 WT, while IFITM3 G95L was pulled down to a
lesser extent (**Figure EV3B**). Together, these results suggest that ectopic IFITM3 can interact
with endosomal Q-SNAREs as well as the R-SNAREs VAMP8 and VAMP7.
We then assessed whether endogenous IFITM3 exhibits SNARE binding activity.
Following transfection of ectopic STX7 into HeLa WT or *IFITM3* KO cells, we found that
ectopic STX7 pulled down endogenous IFITM3 (**Figure 4A**). As a control, pull down of
endogenous IFITM3 by ectopic STX7 was lost in *IFITM3* KO cells (**Figure 3A**). *IFITM3* KO
was specific, as IFITM2 protein levels were unaffected, and did not influence the overall levels
of endolysosomal SNARE proteins (**Figure EV4A**). Moreover, the presence or absence of
IFITM3 did not affect the co-immunoprecipitation between STX7 and other Q-SNAREs STX8
and Vti1b (**Figure EV4B**). We were unable to detect or immunoprecipitate endogenous STX7 in
HeLa cells. However, we succeeded in immunoprecipitating endogenous STX8 and found that it
pulled down endogenous IFITM3 (**Figure 4B**). Additionally, endogenous IFITM3 was also
pulled down by endogenous Vti1b, VAMP8, and VAMP7 (**Figure 4C-4E**). These results
demonstrate that endogenous IFITM3 binds to endolysosomal Q- and R-SNAREs in a direct or
indirect manner. To determine whether IFITM3 can bind SNARE proteins directly, we produced
and purified recombinant IFITM3 (**Figure EV4C and EV4D**) and incubated it with recombinant
STX7 *in vitro* (**Figure EV4E and EV4F**). Immunoprecipitation of recombinant STX7 from the
reaction resulted in pull down of recombinant IFITM3 WT, but this interaction was lost for
IFITM3 F75/78A or IFITM3 G95L (**Figure 4F**). With size exclusion chromatography, we ruled
out that the selective pull down of IFITM3 WT by recombinant STX7 was due to a tendency for
IFITM3 WT to form aggregates *in vitro* (**Figure EV5A**). Overall, we demonstrate for the first
time that IFITM3 is capable of direct interaction with an endosomal Q-SNARE via an R-
SNARE-like motif that is critical for antiviral activity.
Since STX7 is an essential part of the SNARE complexes controlling homotypic late
endosome fusion and heterotypic late endosome fusion, we determined whether IFITM3
regulates the assembly of the STX7-STX8-Vti1b-VAMP8 complex, the STX7-STX8-Vti1b-
VAMP7 complex, or both. STX7, VAMP8, and IFITM3 were ectopically co-expressed in
HEK293T and STX7 was immunoprecipitated to identify its interaction partners. As shown
above, STX7 pulled down IFITM3 WT, while the G95L mutation in IFITM3 abrogated this
interaction (**Figure 5A**). Importantly, STX7 pulled down a reduced amount of VAMP8 in the
presence of IFITM3 relative to Empty Vector. In contrast, IFITM3 G95L did not affect the
STX7-VAMP8 interaction (**Figure 5A**). These findings were confirmed by measuring the
colocalization between STX7-GFP and VAMP8-mCherry in cells expressing IFITM3 WT or
IFITM3 G95L. We found that STX7-GFP colocalization with VAMP8-mCherry was reduced by
IFITM3 WT in a G95-dependent manner (**Figure 5B**). We performed additional experiments
whereby STX7, VAMP7, and IFITM3 were ectopically co-expressed. Here, IFITM3 binding to
STX7 did not inhibit the interaction between STX7 and VAMP7. Instead, the STX7-VAMP7
interaction was slightly elevated in the presence of IFITM3 WT, but not IFITM3 G95L (**Figure
EV5B**). These results indicate that IFITM3 binding to STX7 selectively impairs the interaction
between STX7 and VAMP8.
Since it was previously shown that endocytic viruses including IAV may co-opt the
STX7-STX8-Vti1b-VAMP8 SNARE complex to promote the virus entry process (Pirooz *et al.*,
2014b), we performed co-immunoprecipitation experiments in cells that had been inoculated
with IAV. Interestingly, we noticed that virus addition resulted in enhanced co-
immunoprecipitation between endogenous STX8 and VAMP8 in HEK293T cells (**Figure 5C**).

However, in the presence of ectopic IFITM3 WT, this co-immunoprecipitation was diminished, while co-immunoprecipitation between endogenous STX8 and VAMP7 was enhanced (**Figure 5C**). The IFITM3 G95L mutant, in contrast, co-immunoprecipitated with STX8 to a lesser extent than IFITM3 WT and only marginally impacted the STX8-VAMP8 and STX8-VAMP7 interactions (**Figure 5C**). To address whether endogenous IFITM3 performs a similar function, we immunoprecipitated endogenous STX8 from HeLa. As shown above, endogenous IFITM3 pulls down with endogenous STX8. However, endogenous STX8 pulled down increased quantities of VAMP8 in *IFITM3* KO cells relative to WT cells (**Figure 5D**). Consistently, STX7-GFP colocalized with VAMP8-mCherry to a greater extent in *IFITM3* KO cells compared to WT cells (**Figure EV5C**). These results support a model whereby IFITM3 disfavors the STX7/8-VAMP8 interaction while favoring the STX7/8-VAMP7 interaction. To test whether IFITM3 reduces the assembly of the entire STX7-STX8-Vti1b-VAMP8 SNARE complex involved in homotypic late endosome fusion, we ectopically co-expressed STX7, STX8, Vti1b, and VAMP8 in HEK293T cells. SNARE protein assemblies have been previously characterized as SDS-resistant complexes in whole cell lysates under mildly denaturing conditions (Kubista *et al*, 2004). We identified an SDS-resistant complex approximately 200 kD in size or greater by immunoblotting for VAMP8 (**Figure 6A**) or STX8 (**Appendix Figure S1**). The complex was sensitive to heat, as high molecular weight bands disappeared after boiling lysates (**Figure 6A and Appendix Figure S1**). Consistent with IFITM3 acting as a negative regulator of complex formation, complex abundance was markedly reduced in cells expressing IFITM3 WT (**Figure 6A and Appendix Figure S1**). In contrast, IFITM3 G95L only marginally reduced complex formation (**Figure 6A**). Therefore, by binding STX7/8 via an R-SNARE-like motif and reducing their interaction with VAMP8, IFITM3 impedes formation of the STX7-STX8-Vti1b-VAMP8 complex involved in homotypic late endosome fusion.

Our results showing that IFITM3 uses an R-SNARE-like motif to inhibit assembly of the homotypic late endosome fusion machinery while maintaining, and possibly amplifying, assembly of the heterotypic late endosome-lysosome fusion machinery may explain how IFITM3 redirects incoming virions towards lysosomes for degradation (Feeley *et al.*, 2011; Spence *et al.*, 2018; Suddala *et al.*, 2019). To directly test whether IFITM3 promotes the fusion of late endosomes with lysosomes in living cells, we pulsed cells expressing IFITM3 WT or IFITM3 G95L with Dextran and monitored its trafficking to lysosomes labeled with Magic Red cathepsin substrate. In the presence of IFITM3 WT, Dextran colocalization with lysosomes was enhanced relative to cells expressing Empty Vector or IFITM3 G95L **(Figure 6B)**. When the same assay was performed in HeLa cells, Dextran colocalization with Magic Red was diminished in *IFITM3* KO cells compared to WT cells (**Appendix Figure S1B**). As an alternative approach to measure late endosome-lysosome fusion, we co-transfected cells with Rab7-mCherry and LAMP1-GFP, which label late endosomes and lysosomes, respectively. In cells expressing IFITM3 WT, we observed increased colocalization between Rab7-mCherry and LAMP1-GFP relative to cells expressing Empty Vector or IFITM3 G95L (**Appendix Figure S2**). In contrast, we did not observe extensive colocalization between Rab5-RFP (an early endosome marker) and LAMP1-GFP, and IFITM3 WT did not promote their colocalization (**Appendix Figure S3**). Furthermore, the LAMP1-GFP compartment appeared enlarged and expanded in the presence of IFITM3 WT, which is consistent with enhanced late endosome-lysosome fusion (**Appendix Figures S2 and S3**). While these findings demonstrate that IFITM3 promotes cargo delivery from late endosomes to lysosomes, it remained to be seen whether it promotes endosomal cargo degradation in lysosomes. It was previously reported that IFITM3 accelerates the turnover of the

Epidermal Growth Factor Receptor (EGFR) in lysosomes (Spence *et al.*, 2018). Importantly, the
fate of EGFR in cells is also controlled by the STX7-STX8-Vti1b-VAMP7/8 SNARE machinery
(Futter *et al*, 1996). To confirm this finding, we took advantage of an assay monitoring the
lysosomal turnover of EGFR-GFP by flow cytometry (Inoue *et al*, 2015). We transfected EGFR-
GFP into cells expressing Empty Vector, IFITM3 WT, or IFITM3 G95L and treated them with
EGF to trigger endocytosis of EGFR-GFP. Under these conditions, a portion of EGFR-GFP is
slated for degradation in lysosomes. We found that partial EGFR-GFP loss was detected in HeLa
WT cells between 1 and 2 hrs post-EGF addition. In contrast, we did not detect EGFR-GFP loss
in HeLa *IFITM3* KO over the same time period (**Appendix Figure S4**). Confirming a role for
IFITM3 in accelerating the turnover of EGFR-GFP, we found that EGFR-GFP loss was less
marked and less rapid in cells expressing IFITM3 G95L compared to cells expressing IFITM3
WT (**Appendix Figure S4**). Therefore, IFITM3 facilitates the degradation of endosomal cargo
by inhibiting assembly of the homotypic late endosome fusion machinery and promoting fusion
between late endosomes and lysosomes.
To test the impact of IFITM3 on lysosomal targeting of viral cargo, we examined early
steps of IAV entry into cells using confocal immunofluorescence microscopy. In HEK293T cells
stably expressing IFITM3 WT or IFITM3 G95L, which differ with respect to STX7 binding
potential (**Figure 3A**), IAV was added to cells at a multiplicity of infection of 1 and incubated on
ice for 40 mins. Cells were fed warm medium containing Lysotracker, to visualize acidic
lysosomes, and placed at 37°C to enable synchronized internalization of virus particles. Four
hours later, cells were washed, fixed and immunostained with an antibody against IAV
nucleoprotein (NP), which detects incoming, virion-associated NP as well as de novo
synthesized NP. In cells expressing Empty Vector, nuclear NP accumulation was apparent at 4
hours post-inoculation in roughly 20% of cells, which signals the initiation of virus replication
following successful entry of the virus (i.e. escape from the endocytic compartment) (**Figure 7A**
and 7B). In cells expressing IFITM3 WT, nuclear NP accumulation was virtually absent,
consistent with strong inhibition of cellular entry of IAV as reported previously (Feeley *et al.*,
2011). In contrast, IFITM3 G95L did not reduce nuclear NP accumulation, in agreement with a
loss of antiviral activity exhibited by this mutant (Rahman *et al.*, 2020) (**Figure 7A and 7B**).
Interestingly, we observed a negative correlation between the extent of nuclear NP staining and
the intensity of Lysotracker staining in cells. IFITM3 WT expression resulted in intensification
of Lysotracker fluorescence, consistent with expansion of the lysosomal compartment as
described previously (Feeley *et al.*, 2011). However, expression of IFITM3 G95L did not
(**Figure 7C and 7D**). In cells expressing IFITM3 G95L, most NP protein localized to the nucleus
at four hours post-inoculation. However, some instances of extra-nuclear, bright NP puncta
associated with the Lysotracker-positive compartment could be observed, suggesting that a small
proportion of incoming IAV virions were trafficked to lysosomes in IFITM3 G95L-expressing
cells (**Figure 7D**). However, the occurrence of bright NP puncta colocalizing with Lysotracker-
positive vesicles was enhanced in cells expressing IFITM3 WT (**Figure 7D and Appendix**
Figure S4). In IFITM3 WT cells, NP was found to colocalize with Lysotracker to a greater
extent than in cells expressing IFITM3 G95L (**Figure 7D**). These results support the notion that
inhibition of homotypic late endosome fusion and promotion of heterotypic late endosome fusion
by IFITM3 underlies its ability to promote trafficking of IAV towards lysosomes (**Figure 8**).
Altogether, this body of work demonstrates that endolysosomal SNARE modulation is a key
aspect of the mechanism by which IFITM3 protects cells from invading viruses.
368

Discussion

Our identification of an R-SNARE-like motif in human CD225 proteins suggests that these proteins act as SNARE mimics to regulate SNARE-mediated membrane fusion events. Even though there are CD225 members that lack the polar arginine or glutamine in the central layer characteristic of a canonical SNARE motif, they encode layered hydrophobicity which may still afford some degree of SNARE modulation (**Figure EV1A**). For example, Vti1a is SNARE protein involved in neurotransmission despite encoding an aspartic acid in the central layer (Tang *et al*, 2022) (**Figure 1A**). Moreover, other well-characterized SNARE proteins, like STX8, VAMP8, VAMP7, and Vti1b lack a full complement of hydrophobic layers in their respective SNARE motifs (**Figure 1A**). Since the CD225 family is poorly characterized and contains many proteins with currently unknown functions (Coomer *et al.*, 2021), our discovery of built-in SNARE binding potential within the CD225 domain may serve as a catalyst for uncovering the physiological roles they perform. As such, we provide important insight into the birth and functional expansion of the CD225 domain over the course of evolutionary time.

A limited number of SNARE-like proteins functioning as SNARE mimics have been described before. Two of the best characterized R-SNARE-like proteins in humans are Tomosyn and Amisyn, which adopt VAMP-like protein folds and regulate the same neuronal SNARE complex that PRRT2 does (Hatsuzawa *et al*, 2003; Masuda *et al*, 1998; Scales *et al*, 2002). Furthermore, microbial proteins containing SNARE-like sequence and functionality have been discovered in prokaryotes and viruses (Delevoye *et al*, 2008; King *et al*, 2015; Paumet *et al*, 2009; Shi *et al*, 2016; Wesolowski & Paumet, 2010). Interestingly, phylogenetic evidence suggests that the CD225 domain was introduced into eukaryotes following multiple horizontal transmission events from prokaryotes (Sällman Almén *et al*, 2012). Therefore, it is possible that the SNARE-like motif of CD225 traces its beginnings to a similar, ancient motif in microbes.

IFITM3 was arguably the most completely understood member of the CD225 family, but our finding that it acts as a SNARE assembly modulator significantly boosts our understanding of its key cellular functions. The closely related proteins, IFITM1, IFITM2, IFITM5, and IFITM10, are also likely to interact with SNARE proteins since they all share an R-SNARE-like motif (**Figure 1A**). Interestingly, one of the most significant series of findings with regards to IFITM function was the characterization of a conserved amphipathic alpha helix in its amino terminus. This helix was shown to be essential for the antiviral activity of IFITM3 (Chesarino *et al.*, 2017) and necessary for the ability of IFITM3 to reduce cellular membrane fluidity (Rahman *et al.*, 2020). Following our discovery here, we now know that this amphipathic helix is immediately adjacent to, or part of, an R-SNARE-like motif (**Figure 2A**). Interestingly, a SNARE protein in yeast known as Spo20 also contains an amphipathic alpha helix amino terminal to its SNARE motif, resembling the structural organization of IFITM3 (Nakanishi *et al*, 2004). Moreover, another group of SNARE binding proteins known as complexins are also bestowed with an amphipathic helix, and they use it to induce membrane curvature and stabilize fusion pores produced by SNARE complexes (Courtney *et al*, 2022). Therefore, it is possible that IFITM3 employs its amphipathic helix in conjunction with its R-SNARE-like motif to sculpt membranes at precisely the sites where endolysosomal SNARE assemblies are triggering membrane fusion. Other structural features lend additional support to our case that IFITM3 is a SNARE-like protein. Some SNARE proteins encode a single transmembrane domain to directly anchor into vesicular or target membranes (Jahn & Scheller, 2006), and IFITM3 is similar in this regard (Ling *et al.*, 2016). Additionally, palmitoylation is a post-translational modification of

cysteine residues that promotes membrane localization, and IFITM3 and various SNARE
proteins are known to be palmitoylated (Fukasawa *et al*, 2004; Hach *et al.*, 2013; Prekeris *et al*,
2000; Veit *et al*, 1996; Yount *et al*, 2012).

Notably, the relatively limited structural information previously available for IFITM3 did
not indicate the presence of a continuous alpha helix reminiscent of a SNARE motif. In isolation,
the region comprising the R-SNARE-like sequence motif of IFITM3 was previously thought to
form one or two amphipathic helices followed by a disordered, intracellular loop (Chesarino *et*
al., 2017; Ling *et al.*, 2016). The structure of another CD225 protein, PRRT2, was posited to
contain a similarly disordered, intracellular loop as well (Rossi *et al*, 2016). The typical SNARE
fold characteristic of a SNARE motif may only form in the context of a coiled-coil assembly of
multiple SNARE alpha helices (trans-SNARE complex). Our description of IFITM3 as a
SNARE-like protein capable of interacting with endosomal SNARE proteins suggests that
multiple protein folds and membrane topologies of IFITM3 may be possible, depending on the
presence of interacting partners (such as STX7). Thus, attempts to structurally characterize
IFITM3 in complex with STX7 or other endosomal SNAREs may provide substantial structural
insight that has been lacking.

Regarding the structural interface between IFITM3 and endosomal SNARE proteins, the
stoichiometry of the interactions remains unclear. We previously characterized a GxxxG motif
present in CD225 proteins that enables homomultimerization and which is essential to the
functions of PRRT2 and IFITM3 (Rahman *et al.*, 2020). Here we show that mutation of the
GxxxG motif in PRRT2 (G305W), TUSC5 (G141W), or IFITM3 (G95L) caused loss of binding
with Q-SNAREs SNAP-25, STX4, or STX7, respectively (**Figure 1B, Figure EV1C and
EV1D, and Figure 3A**). These glycines reside adjacent to the +3 hydrophobic layer (**Figure 1A**)
and may disrupt the structural integrity of the R-SNARE-like motif. Alternatively, these findings
may signal a requirement for CD225 proteins to multimerize prior to gaining SNARE binding
potential. Another possibility is that the GxxxG motif in CD225 proteins not only controls
homomultimerization but also impacts binding with other proteins including SNAREs.

What is more certain is that this previously unrecognized ability of IFITM3 to bind
endosomal SNARE proteins and inhibit homotypic late endosome fusion advances our
understanding of how IFITM3 inhibits the cellular entry of a diverse spectrum of enveloped and
non-enveloped viruses (Majdoul & Compton, 2021). By showing that IFITM3 inhibits
homotypic late endosome fusion while reinforcing heterotypic late endosome fusion, whereby
late endosomes fuse with lysosomes, we provide an explanation for how IFITM3 overexpression
causes expansion of the endolysosomal compartment and degradation of virions within it (Feeley
et al., 2011). Taken together with previous findings, we propose a revised model for the
molecular mechanism of IFITM3-mediated antiviral activity that is two-pronged: 1) IFITM3
traps incoming virions in late endosomes by inhibiting membrane fusion between the viral and
cellular lipid bilayers; and 2) IFITM3 promotes the fusion of late endosomes with lysosomes to
facilitate the degradation of trapped viral cargo.

In addition to blocking infection through inhibition of virus entry into cells, IFITM3 also
performs an antiviral function in cells that are already infected—it has been shown to interact
with and inhibit the function of viral fusogens (known as viral envelope glycoproteins) found in
virions, which in turn reduces the infectivity of said virions (Compton *et al*, 2014; Tartour *et al*,
2014; Wang *et al*, 2017; Yu *et al*, 2015). Remarkably, viral fusogens share structural and
functional similarities to SNARE proteins, including heptad repeats and the formation of coiled-
coil assemblies to drive membrane merger (Skehel & Wiley, 1998; Sollner, 2004). Therefore, our

description of an R-SNARE-like motif in IFITM3 may reveal the molecular basis by which
IFITM3 interacts with both cellular and viral fusion machinery to control virus infections at
multiple levels.
464
465 **Methods**
466
Tissue culture, cell lines, and expression constructs
HEK293T (CRL-3216) and HeLa (CCL-2) were purchased from ATCC and cultivated at
37°C and 5% CO_2 in DMEM (Gibco) complemented with 10% fetal bovine serum (Hyclone)
and 1% penicillin-streptomycin (Gibco). HeLa *IFITM3* KO cells were generated as previously
described (Shi *et al*, 2018). pQCXIP retroviral vectors encoding human IFITM3 (tagged with
FLAG on amino terminus), PRRT2 (tagged with FLAG on carboxy terminus), or TUSC5 (tagged
with FLAG on the amino terminus) were previously described (Rahman *et al.*, 2020) or
synthesized by Integrated DNA Technologies (IDT) as gBlock fragments and cloned into
pQCXIP using BamH1 and EcoR1 restriction enzymes. Mutations were introduced via
QuikChange Lightning Site-Directed Mutagenesis (Agilent). HEK293T stably expressing
pQCXIP-Empty Vector, pQCXIP-FLAG-IFITM3 WT, or pQCXIP-FLAG-IFITM3 G95L,
encoding amino-terminal FLAG tag, were described previously(Rahman *et al.*, 2020).
pcDNA3.1 encoding SNARE proteins (SNAP25, STX1A, STX4, STX7, STX8, Vti1b, VAMP8,
and VAMP7) tagged with HA or Myc at the amino terminus were synthesized by IDT as gBlock
fragments and cloned into pcDNA3.1 using BamH1 and EcoR1 restriction enyzmes.
Transfections were performed with Lipofectamine 2000 (Invitrogen). All cell lines tested
negative for mycoplasma.
484
Antibodies, immunoblotting, and immunoprecipitations
Whole cell lysis was performed in a buffer containing 50 mM Tris-HCl pH 7.4, 1.0%
TritonX-100 (Sigma), 150 mM NaCl, and 1 mM EDTA. Immunoprecipitation was performed as
follows: antibodies were loaded with Dynabeads (Invitrogen) for 1 hr at 4°C while rotating;
Dynabead-conjugated antibodies were added to whole cell lysates for 3 hr at 4°C while rotating
to capture antibody-antigen complexes; immunoprecipitated fractions were isolated using the
DynaMag-2 magnet (Invitrogen) and washed three times with lysis buffer prior to addition of
NuPage LDS Sample Buffer (Invitrogen) and NuPage Sample Reducing Agent (Invitrogen); the
immunoprecipitated and non-immunoprecipitated fractions were heat denatured at 100°C for 5
min; samples were loaded into Criterion XT 12% Bis-Tris polyacrylamide gels (Bio-Rad) for
SDS-PAGE using NuPAGE MES SDS Running Buffer (Invitrogen). Proteins were transferred to
Amersham Protran Nitrocellulose Membrane (GE Healthcare), and membranes were blocked
with Intercept Blocking Buffer-PBS (Li-COR) prior to incubation with primary and secondary
antibodies. The following antibodies were used in this study: anti-STX8 (110-083; Synaptic
Systems); anti-STX7 (110-072; Synaptic Systems), anti-Vti1b (164-002; Synaptic Systems),
anti-VAMP8 (104-302; Synaptic Systems), anti-VAMP7 (ab36195; Abcam), anti-HA (901514,
clone 16B12; Biolegend), anti-HA (ab9110; Abcam (this was used for immunoprecipitation)),
anti-Myc (C3956, Sigma), anti-FLAG M2 (F1804; Sigma), anti-IFITM3 (ab109429; Abcam),
anti-IFITM2/3 (66081-1-Ig, Proteintech), anti-tubulin (and anti-actin (SC-47778; Santa Cruz
Biotechnology). Goat anti-mouse and goat anti-rabbit secondary antibodies conjugated to
DyLight 680 or 800 (Li-COR) and the Li-COR Odyssey CLx imaging system were used for
generating immunoblots. Membrane images were analyzed using ImageStudioLite (Li-COR).

Sequence retrieval and protein alignments

Protein sequences for CD225 proteins, Q-SNAREs, and R-SNAREs were retrieved from UniProt. Multi-sequence alignments were performed with MEGA11 and manually trimmed to the 53-residue SNARE motif. UniProt numbers for SNAREs are as follows: syntaxin1, Q16623; syntaxin4, Q12846; syntaxin 6, O43752; syntaxin7, O15400; syntaxin8, Q9UNK0; SNAP23, O00161; Vti1a, Q96AJ9; Vti1b, Q9UEU0; VAMP1, P23763; VAMP2, P63027; VAMP3, Q15836; VAMP5, O95183; VAMP7, P51809; VAMP8, Q9BV40; Ykt6, O15498; Syn8p, P31377; Tomosyn/STXBP5, Q5T5C0; Amisyn/STXBP6, Q8NFX7.

Recombinant IFITM3 protein production

Recombinant human IFITM3 protein (WT, F65/68A, and G95L) was produced by cloning the nucleotide sequence appended with a Strep-II tag at the amino terminus into pET3XC and transforming it into Rosetta 2 DE3 pLysS Competent Cells (Sigma). A single colony of transformed cells was grown in LB overnight at 37°C. One mL of the culture was expanded in 200 mL 2YT medium (Sigma) at 37°C until the optical density reached 0.4, and the temperature was lowered to 18°C for 1 hr before induction with 0.4 mM IPTG (Tecknova) for 20 hr. Pelleted cells were frozen at -80°C before proceeding to protein purification. Thawed cells were resuspended in ice cold lysis buffer (at 10% w/v) consisting of 20 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mM DTT, 0.5 mg/ml lysozyme (Sigma), 1 mM PMSF (Sigma), 0.025% (v/v) Triton X-100 (Sigma), and 1X Complete Protease Inhibitors (Roche). Sample was stirred at 4°C for 20 min before applying 2 freeze-thaw cycles by transferring the sample container between dry ice and a room temperature water bath. The thawed lysate was stirred at room temperature for 15 min after adding 5 U/mL benzonase (Sigma) prior to pulse sonication for 30 s at 4°C. Sample was clarified by centrifugation at 5000 g for 10 min and the supernatant was further centrifuged at 40000 g for 60 min. The pellet was thoroughly resuspended in the lysis buffer (modified to include 1 mM EDTA and excluding lysozyme) and centrifuged at 40000 g for 60 min. This process was then performed a second time. The pellet was extracted twice with 20 mM Tris-HCl pH 7.6, 100 mM NaCl, 20% glycerol, 2% (v/v) Anapoe-X-100 (Anatrace), 1 mM DTT (Gold Bio), and 0.1 mM AEBSF (Santa Cruz Biotechnology) at 4°C while stirring for 4 hr each. The protein in the pellet was extracted with 20 mM Tris-HCl pH 7.6, 0.6% Sarkosyl (w/v) (Sigma), and 2 mM DTT. Strep-II-fused IFITM3 was purified by affinity chromatography using Strep-Tactin Sepharose Resin (IBA Lifesciences). Protein was >90% pure as determined by SDS-PAGE and Coomassie blue staining. Protein concentration was determined by Bio-Rad Protein Assay and stored at a concentration of 15-30 mg/mL at -80°C. In the final reaction mixture of purified, recombinant IFITM3, the Sarkosyl concentration was 0.00002%.

Size exclusion chromatography of recombinant IFITM3

Size exclusion chromatography was performed on a Superose 12 10/300 GL column (GE Healthcare). The column was equilibrated with a buffer consisting of 20 mM Tris-HCl pH 8.0, 120 mM NaCl, 0.2% (v/v) TritonX-100, and 1 mM TCEP. 150 µg recombinant IFITM3 (WT, F75/78A, or G95L) was diluted into 300 µL of buffer and injected into the column. One mL fractions were collected and subjected to SDS-PAGE and Coomassie blue staining.

In vitro protein-protein co-immunoprecipitation

Two µg of recombinant Strep-II tagged IFITM3 WT or F75/78A or G95L were incubated with 2 µg of recombinant His-tagged STX7 (IHUSTX7RN6HISLY50UG; Innovative Research) in 0.3 mL of binding buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 0.2% TritonX-100, and 0.1% BSA) overnight at 4°C. The samples were incubated with 1 µg of anti-STX7 antibody for 1 hr. The antibody-antigen complex was captured with 15 uL of Dynabeads (Invitrogen). After washing the samples 3 times with binding buffer (lacking BSA), proteins captured by beads using the DynaMag-2 were solubilized in 20 uL of 1X NuPAGE LDS Sample Buffer and 1X NuPAGE Sample Reducing Reagent (Invitrogen), and heat denatured at 100°C for 5 min. SDS-PAGE and immunoblotting were performed and proteins were detected as described above.

Structural modeling of the R-SNARE-like motif of IFITM3

The R-SNARE-like motif of IFITM3 (residues 55-113) and the R-SNARE motif of VAMP8 (residues 13-65) were compared by predictive protein structure alignment and comparison algorithm TM-align (Zhang & Skolnick, 2005). A TM score of 0.75847 was recorded, indicating that the two regions are likely to adopt the same alpha helical protein fold. Structural comparison between the R-SNARE-like motif of IFITM3 and the R-SNARE motif of VAMP8, which was previously crystallized as part of the STX7-STX8-Vti1b-VAMP8 trans-SNARE complex (PDB: 1GL2) (Antonin *et al.*, 2002), was performed using Alphafold version 3 (Jumper & Hassabis, 2022) with assistance from the Colabfold server (Mirdita *et al.*, 2022). A structure for the R-SNARE-like motif of IFITM3 was predicted using the R-SNARE motif of VAMP8 as a template. The Alphafold structure was then aligned with that of VAMP8 using the FATCAT server (Li *et al.*, 2020). The aligned structures were then visualized and reoriented for figure presentation using ChimeraX (Meng *et al*, 2023).

Influenza A Virus infection

Influenza A Virus [A/PR/8/34 (PR8), H1N1] supplied as clarified allantoic fluid was purchased from Charles River Laboratories. Infectious virus titers were calculated using a flow cytometry-based method in HEK293T cells (Grigorov *et al*, 2011), and infections were performed as follows: HEK293T cells (transiently transfected with 1.5 µg pQCXIP-Empty Vector, pQCXIP-FLAG-IFITM3 WT, or pQCXIP-FLAG-IFITM3 G95L were seeded in 24-well plates (50,000 per well) overnight and overlaid with virus diluted in 225 µL of complete DMEM (multiplicity of infection = 0.01) for approximately 18 hr. Cells were washed with 1X D-PBS (Gibco), detached with Trypsin-EDTA (Gibco), fixed/permeabilized with Cytofix/Cytoperm (BD), immunostained with anti-IAV NP (ab20343; Abcam), and analyzed on a LSRFortessa flow cytometer (BD).

Influenza A Virus cellular entry assay

An 8-well µ-Slide dish (80826; Ibidi) was coated with 3 mg/mL PureCol (Advanced Biomatrix) for 1 hr at room temperature and then allowed to dry overnight. HEK293T stably expressing pQCXIP-Empty Vector, pQCXIP-FLAG-IFITM3 WT, or pQCXIP-FLAG-IFITM3 G95L were seeded at 20,000 cells per well in DMEM completed with 10% fetal bovine serum and 1% penicillin-streptomycin and incubated at 37°C overnight. Cells were placed on ice for 5 min and then remained on ice while medium was removed and replaced with 120 µL complete DMEM containing Influenza A virus PR8 (multiplicity of infection = 1). Cells mock inoculated with PBS served as a negative control. Inoculated cells were incubated on ice for 40 min to allow for virus adhesion. Medium was removed, cells were washed twice with D-PBS, and medium

was replaced with 150 µL complete DMEM containing 50 nM Lysotracker Deep Red (L12492;
Invitrogen) and incubated at 37°C for 4 hr. Medium was removed, cells were washed twice with
D-PBS, and cells were fixed/permeabilized with Cytofix/Cytoperm (BD) for 10 min at room
temperature. Cells were washed twice with PermWash buffer (BD) and blocked with Intercept
Blocking Buffer (PBS) (Li-COR) for 1 hr at room temperature. Cells were immunostained with
anti-NP (BE0159; InvivoMab) at a 1:200 dilution in Intercept Antibody Diluent (PBS) (Li-COR)
for 1 hr at room temperature. Cells were washed twice in PermWash buffer and goat anti-mouse
IgG (H+L) Alexa Fluor 488 secondary antibody (Invitrogen) at 1:300 dilution in Intercept
Antibody Diluent (PBS) was added for 1 hr at room temperature. Cells were washed twice in
PermWash Buffer and Hoechst 33342 (H3570; Invitrogen) was added for 5 min at room
temperature. Cells were washed once in PermWash Buffer and overlaid with 200 µL D-PBS for
image acquisition on a Leica Stellaris 5 confocal microscope using the 63X oil objective.
Confocal Z stacks of 20-30 optical sections were acquired for each field of view, and multiple
fields were imaged per condition. Images were extracted and subjected to analysis in Fiji. To
quantify Lysotracker staining, the Corrected Total Cell Fluorescence (CTCF) was measured for
the middle Z slice of the entire field. To quantify nuclear NP accumulation, colocalization
between NP and Hoechst was measured for the middle Z slick of each cell in the field and a ratio
of NP+ nuclei: total nuclei was calculated.
616
Late endosome-lysosome fusion assay with Dextran pulse-chase and Magic Red labeling
HEK293T cells stably expressing Empty Vector, IFITM3 WT-FLAG, or IFITM3 G95L-
FLAG or HeLa cells (WT or *IFITM3* KO) were seeded in 35 mm low µ-Dishes (80136; Ibidi)
coated with 3 mg/mL PureCol (Advanced Biomatrix) at 50,000 cells per well in DMEM
completed with 10% fetal bovine serum and 1% penicillin-streptomycin and incubated at 37°C
overnight. Dextran Alexa Fluor 488 (10,000 MW) (D22910; Invitrogen) was added to cells at a
concentration of 25 µg/mL for 2 hrs at 37°C. Dextran-containing medium was then removed,
cells were washed three times with D-PBS, fresh DMEM was added, and cells were incubated
for 1 hr at 37°C. Cells were washed once with FluoroBrite DMEM (Gibco) completed with 10%
fetal bovine serum and 1% penicillin-streptomycin and incubated with Magic Red cathepsin
substrate (ab270772; Abcam) (from 250X stock in DMSO, a final concentration of 1X was used)
for 5 mins at 37°C. Live cell image acquisition was performed on a Leica Stellaris 5 confocal
microscope using the 63X oil objective.
630
Confocal fluorescence microscopy
HEK293T cells stably expressing pQCXIP-Empty Vector, pQCXIP-FLAG-IFITM3 WT,
or pQCXIP-FLAG-IFITM3 G95L or HeLa cells (WT or *IFITM3* KO) were seeded in DMEM
completed with 10% fetal bovine serum and 1% penicillin-streptomycin at 500,000 cells per well
in a 6-well plate and incubated at 37°C overnight. Cells were transfected with 0.5 µg of the
following plasmids: pMRXIP-GFP-STX7 (45921; Addgene), pmCherry-N1-VAMP8 (92424;
Addgene), pEGFP-N3-LAMP1 (34831; Addgene), pmRFP-C3-Rab5 (14437; Addgene), or
pmCherry-Rab7a-7 (55127; Addgene) using Lipofectamine 2000 (Invitrogen). Medium was
replaced 6 hrs post-transfection, and cells were incubated at 37°C for 18 hrs. Cells were washed
once with D-PBS and fixed with Cytofix/Cytoperm (BD). For immunofluorescence analysis of
IFITM3 expression, immunostaining was performed with anti-FLAG M2 (F1804; Sigma) in
fixed cells.
643

EGFR-GFP degradation assay

HEK293T cells stably expressing pQCXIP-Empty Vector, pQCXIP-FLAG-IFITM3 WT, or pQCXIP-FLAG-IFITM3 G95L or HeLa cells (WT or *IFITM3* KO) were seeded in DMEM completed with 10% fetal bovine serum and 1% penicillin-streptomycin at 500,000 cells per well in a 6-well plate and incubated at 37°C overnight. Cells were transfected with 0.5 µg of EGFR-GFP using Lipofectamine 2000. Medium was replaced 6 hrs post-transfection, and cells were incubated at 37°C for 18 hrs. Recombinant EGF (R&D Systems) was added to cells and, at the indicate time point, cells were washed once with D-PBS and fixed with Cytofix/Cytoperm (BD). The percentage of EGFR-GFP+ cells was measured by flow cytometry on an LSRFortessa (BD).

Statistics

Statistical differences were determined with one-way ANOVA test or student's t test corrected for multiple comparisons, using an alpha cut-off of 0.05. All tests were performed as two-tailed and unpaired. Test type and *P* values are reported in the figure captions.

Data deposition and availability

This study includes no data deposited in external repositories. All data are available in the Source Data files.

Acknowledgements

We would like to thank Alexis Schirling for assisting in molecular cloning of SNARE proteins and Guoli Shi for assisting with confocal immunofluorescence microscopy. This work was supported by funding from the Intramural Research Program, National Institutes of Health.

Disclosure and Competing Interests Statement

The authors declare no competing interests.

References

Advani RJ, Yang B, Prekeris R, Lee KC, Klumperman J, Scheller RH (1999) VAMP-7 mediates vesicular transport from endosomes to lysosomes. *J Cell Biol* 146: 765-776

Antonin W, Fasshauer D, Becker S, Jahn R, Schneider TR (2002) Crystal structure of the endosomal SNARE complex reveals common structural principles of all SNAREs. *Nat Struct Biol* 9: 107-111

Bailey CC, Huang IC, Kam C, Farzan M (2012) Ifitm3 limits the severity of acute influenza in mice. *PLoS Pathogens* 8: e1002909

Beaton N, Rudigier C, Moest H, Müller S, Mrosek N, Röder E, Rudofsky G, Rülicke T, Ukropec J, Ukropcova B *et al* (2015) TUSC5 regulates insulin-mediated adipose tissue glucose uptake by modulation of GLUT4 recycling. *MOLMET* 4: 795-810

Becker F, Schubert J, Striano P, Anttonen AK, Liukkonen E, Gaily E, Gerloff C, Muller S, Heussinger N, Kellinghaus C *et al* (2013) PRRT2-related disorders: further PKD and ICCA cases and review of the literature. *J Neurol* 260: 1234-1244

Chesarino NM, Compton AA, McMichael TM, Kenney AD, Zhang L, Soewarna V, Davis M, Schwartz O, Yount JS (2017) IFITM3 requires an amphipathic helix for antiviral activity. *EMBO Reports* 18: e201744100-201744112

Chesarino NM, McMichael TM, Yount JS (2014) Regulation of the trafficking and antiviral
activity of IFITM3 by post-translational modifications. *Future Microbiology* 9: 1151-1163
Coleman J, Jouannot O, Ramakrishnan SK, Zanetti MN, Wang J, Salpietro V, Houlden H,
Rothman JE, Krishnakumar SS (2018) PRRT2 Regulates Synaptic Fusion by Directly
Modulating SNARE Complex Assembly. *Cell Reports* 22: 820-831
Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, Casartelli N,
Schwartz O (2014) IFITM Proteins Incorporated into HIV-1 Virions Impair Viral Fusion and
Spread. *Cell Host Microbe* 16: 736-747
Compton AA, Roy N, Porrot F, Billet A, Casartelli N, Yount JS, Liang C, Schwartz O (2016)
Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral
specificity. *EMBO Reports* 17: 1657-1671
Coomer CA, Rahman K, Compton AA (2021) CD225 Proteins: A Family Portrait of Fusion
Regulators. *Trends in Genetics* 7: 1-4
Courtney KC, Wu L, Mandal T, Swift M, Zhang Z, Alaghemandi M, Wu Z, Bradberry MM, Deo
C, Lavis LD *et al* (2022) The complexin C-terminal amphipathic helix stabilizes the fusion pore
open state by sculpting membranes. *Nat Struct Mol Biol* 29: 97-107
Delevoye C, Nilges M, Dehoux P, Paumet F, Perrinet S, Dautry-Varsat A, Subtil A (2008)
SNARE protein mimicry by an intracellular bacterium. *PLoS Pathogens* 4: e1000022
Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB (2014) IFITM3 restricts
influenza A virus entry by blocking the formation of fusion pores following virus-endosome
hemifusion. *PLoS Pathogens* 10: e1004048
Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C (2015) The evolving spectrum of
PRRT2-associated paroxysmal diseases. *Brain* 138: 3476-3495
Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS,
Adams DJ *et al* (2012) IFITM3 restricts the morbidity and mortality associated with influenza.
Nature 484: 519-523
Fasshauer D, Sutton RB, Brunger AT, Jahn R (1998) Conserved structural features of the
synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs. *Proc Natl Acad Sci*
U S A 95: 15781-15786
Fazakerley DJ, Naghiloo S, Chaudhuri R, Koumanov F, Burchfield JG, Thomas KC, Krycer JR,
Prior MJ, Parker BL, Murrow BA *et al* (2015) Proteomic Analysis of GLUT4 Storage Vesicles
Reveals Tumor Suppressor Candidate 5 (TUSC5) as a Novel Regulator of Insulin Action in
Adipocytes. *J Biol Chem* 290: 23528-23542
Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen L-M, Gaiha GD, Ryan BJ, Donis RO,
Elledge SJ *et al* (2011) IFITM3 inhibits influenza A virus infection by preventing cytosolic entry.
PLoS Pathogens 7: e1002337
Fukasawa M, Varlamov O, Eng WS, Sollner TH, Rothman JE (2004) Localization and activity of
the SNARE Ykt6 determined by its regulatory domain and palmitoylation. *Proc Natl Acad Sci U*
S A 101: 4815-4820
Futter CE, Pearse A, Hewlett LJ, Hopkins CR (1996) Multivesicular endosomes containing
internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes. *J Cell*
Biol 132: 1011-1023
Grigorov B, Rabilloud J, Lawrence P, Gerlier D (2011) Rapid Titration of Measles and Other
Viruses: Optimization with Determination of Replication Cycle Length. *PLoS ONE* 6: e24135-
24112

Guo X, Steinkühler J, Marin M, Li X, Lu W, Dimova R, Melikyan GB (2021) Interferon-Induced Transmembrane Protein 3 Blocks Fusion of Diverse Enveloped Viruses by Altering Mechanical Properties of Cell Membranes. *ACS Nano* 15(5): 8155-8170

Hach JC, McMichael T, Chesarino NM, Yount JS (2013) Palmitoylation on Conserved and Nonconserved Cysteines of Murine IFITM1 Regulates Its Stability and Anti-Influenza A Virus Activity. *Journal of Virology* 87: 9923-9927

Han J, Pluhackova K, Bockmann RA (2017) The Multifaceted Role of SNARE Proteins in Membrane Fusion. *Front Physiol* 8: 5

Hatsuzawa K, Lang T, Fasshauer D, Bruns D, Jahn R (2003) The R-SNARE motif of tomosyn forms SNARE core complexes with syntaxin 1 and SNAP-25 and down-regulates exocytosis. *J Biol Chem* 278: 31159-31166

Hong W (2005) SNAREs and traffic. *Biochim Biophys Acta* 1744: 493-517

Inoue H, Matsuzaki Y, Tanaka A, Hosoi K, Ichimura K, Arasaki K, Wakana Y, Asano K, Tanaka M, Okuzaki D *et al* (2015) γ-SNAP stimulates disassembly of endosomal SNARE complexes and regulates endocytic trafficking pathways. *J Cell Sci* 128: 2781-2794

Jahn R, Scheller RH (2006) SNAREs — engines for membrane fusion. *Nat Rev Mol Cell Bio* 7: 631-643

John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, Smith SE, Elia AEH, Everitt AR, Vora M *et al* (2013) The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. *Journal of Virology* 87: 7837-7852

Jumper J, Hassabis D (2022) Protein structure predictions to atomic accuracy with AlphaFold. *Nat Methods* 19: 11-12

King NP, Newton P, Schuelein R, Brown DL, Petru M, Zarsky V, Dolezal P, Luo L, Bugarcic A, Stanley AC *et al* (2015) Soluble NSF attachment protein receptor molecular mimicry by a Legionella pneumophila Dot/Icm effector. *Cell Microbiol* 17: 767-784

Klein S, Golani G, Lolicato F, Lahr C, Beyer D, Herrmann A, Wachsmuth-Melm M, Reddmann N, Brecht R, Hosseinzadeh M *et al* (2023) IFITM3 blocks influenza virus entry by sorting lipids and stabilizing hemifusion. *Cell Host Microbe* 31: 616-633 e620

Kloepper TH, Kienle CN, Fasshauer D (2007) An elaborate classification of SNARE proteins sheds light on the conservation of the eukaryotic endomembrane system. *Mol Biol Cell* 18: 3463-3471

Kubista H, Edelbauer H, Boehm S (2004) Evidence for structural and functional diversity among SDS-resistant SNARE complexes in neuroendocrine cells. *J Cell Sci* 117: 955-966

Li C, Guo XR, Dong ZM, Gao YJ, Li XL, Zhang L, Zheng HQ, Wang LL, Lu C, Tian XX *et al* (2024) Novel interacting proteins identified by tandem affinity purification and mass spectrometry associated with IFITM3 protein during PDCoV infection. *Int J Biol Macromol* 277: 132755

Li K, Markosyan RM, Zheng Y-M, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC *et al* (2013) IFITM proteins restrict viral membrane hemifusion. *PLoS Pathogens* 9: e1003124

Li Z, Jaroszewski L, Iyer M, Sedova M, Godzik A (2020) FATCAT 2.0: towards a better understanding of the structural diversity of proteins. *Nucleic Acids Res* 48: W60-W64

Ling S, Zhang C, Wang W, Cai X, Yu L, Wu F, Zhang L, Tian C (2016) Combined approaches of EPR and NMR illustrate only one transmembrane helix in the human IFITM3. *Scientific Reports* 6: 1-8

Ma H, Feng S, Deng X, Wang L, Zeng S, Wang C, Ma X, Sun H, Chen R, Du S *et al* (2018) A
PRRT2 variant in a Chinese family with paroxysmal kinesigenic dyskinesia and benign familial
infantile seizures results in loss of interaction with STX1B. *Epilepsia* 59: 1621-1630
Majdoul S, Compton AA (2021) Lessons in self-defence: inhibition of virus entry by intrinsic
immunity. *Nat Rev Immunol* 22(6): 339-352
Masuda ES, Huang BC, Fisher JM, Luo Y, Scheller RH (1998) Tomosyn binds t-SNARE
proteins via a VAMP-like coiled coil. *Neuron* 21: 479-480
Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, Ferrin TE (2023)
UCSF ChimeraX: Tools for structure building and analysis. *Protein Sci* 32: e4792
Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M (2022) ColabFold:
making protein folding accessible to all. *Nat Methods* 19: 679-682
Mullock BM, Smith CW, Ihrke G, Bright NA, Lindsay M, Parkinson EJ, Brooks DA, Parton RG,
James DE, Luzio JP *et al* (2000) Syntaxin 7 is localized to late endosome compartments,
associates with Vamp 8, and Is required for late endosome-lysosome fusion. *Mol Biol Cell* 11:
3137-3153
Nakanishi H, de los Santos P, Neiman AM (2004) Positive and negative regulation of a SNARE
protein by control of intracellular localization. *Mol Biol Cell* 15: 1802-1815
Paumet F, Wesolowski J, Garcia-Diaz A, Delevoye C, Aulner N, Shuman HA, Subtil A, Rothman
JE (2009) Intracellular Bacteria Encode Inhibitory SNARE-Like Proteins. *PLoS ONE* 4: e7375-
7379
Pirooz S, He S, O'Connell D, Khalilzadeh P, Yang Y, Liang C (2014a) Viruses customize
autophagy protein for efficient viral entry. *Autophagy* 10: 1355-1356
Pirooz SD, He S, Zhang T, Zhang X, Zhao Z, Oh S, O'Connell D, Khalilzadeh P, Amini-Bavil-
Olyaee S, Farzan M *et al* (2014b) UVRAG is required for virus entry through combinatorial
interaction with the class C-Vps complex and SNAREs. *Proc Natl Acad Sci U S A* 111: 2716-
2721
Prekeris R, Klumperman J, Scheller RH (2000) Syntaxin 11 is an atypical SNARE abundant in
the immune system. *Eur J Cell Biol* 79: 771-780
Prekeris R, Yang B, Oorschot V, Klumperman J, Scheller RH (1999) Differential roles of
syntaxin 7 and syntaxin 8 in endosomal trafficking. *Mol Biol Cell* 10: 3891-3908
Pryor PR, Mullock BM, Bright NA, Lindsay MR, Gray SR, Richardson SCW, Stewart A, James
DE, Piper RC, Luzio JP (2004) Combinatorial SNARE complexes with VAMP7 or VAMP8
define different late endocytic fusion events. *EMBO Reports* 5: 590-595
Rahman K, Coomer CA, Majdoul S, Ding SY, Padilla-Parra S, Compton AA (2020) Homology-
guided identification of a conserved motif linking the antiviral functions of IFITM3 to its
oligomeric state. *eLife* 9: 975-925
Rahman K, Datta SAK, Beaven AH, Jolley AA, Sodt AJ, Compton AA (2022) Cholesterol Binds
the Amphipathic Helix of IFITM3 and Regulates Antiviral Activity. *J Mol Biol* 434: 167759
Rossi P, Sterlini B, Castroflorio E, Marte A, Onofri F, Valtorta F, Maragliano L, Corradi A,
Benfenati F (2016) A Novel Topology of Proline-rich Transmembrane Protein 2 (PRRT2). *J Biol
Chem* 291: 6111-6123
Sällman Almén M, Bringeland N, Fredriksson R, Schiöth HB (2012) The Dispanins: A Novel
Gene Family of Ancient Origin That Contains 14 Human Members. *PLoS ONE* 7: e31961
Scales SJ, Hesser BA, Masuda ES, Scheller RH (2002) Amisyn, a novel syntaxin-binding protein
that may regulate SNARE complex assembly. *J Biol Chem* 277: 28271-28279

Shi G, Ozog S, Torbett BE, Compton AA (2018) mTOR inhibitors lower an intrinsic barrier to
virus infection mediated by IFITM3. *Proc Natl Acad Sci U S A* 115: E10069-E10078
Shi G, Schwartz O, Compton AA (2017) More than meets the I: the diverse antiviral and cellular
functions of interferon-induced transmembrane proteins. *Retrovirology* 14: 1-11
Shi X, Halder P, Yavuz H, Jahn R, Shuman HA (2016) Direct targeting of membrane fusion by
SNARE mimicry: Convergent evolution of Legionella effectors. *Proc Natl Acad Sci U S A* 113:
8807-8812
Skehel JJ, Wiley DC (1998) Coiled coils in both intracellular vesicle and viral membrane fusion.
Cell 95: 871-874
Sollner TH (2004) Intracellular and viral membrane fusion: a uniting mechanism. *Curr Opin Cell*
Biol 16: 429-435
Spence JS, He R, Hoffmann H-H, Das T, Thinon E, Rice CM, Peng T, Chandran K, Hang HC
(2018) IFITM3 directly engages and shuttles incoming virus particles to lysosomes. *Nat Chem*
Biol 1: 1-15
St-Denis JF, Cushman SW (1998) Role of SNARE's in the GLUT4 translocation response to
insulin in adipose cells and muscle. *J Basic Clin Physiol Pharmacol* 9: 153-165
Stöckli J, Fazakerley DJ, James DE (2011) GLUT4 exocytosis. *J Cell Sci* 124: 4147-4159
Suddala KC, Lee CC, Meraner P, Marin M, Markosyan RM, Desai TM, Cohen FS, Brass AL,
Melikyan GB (2019) Interferon-induced transmembrane protein 3 blocks fusion of sensitive but
not resistant viruses by partitioning into virus-carrying endosomes. *PLoS Pathogens* 15:
e1007532-1007535
Sudhof TC (2004) The synaptic vesicle cycle. *Annu Rev Neurosci* 27: 509-547
Sutton RB, Fasshauer D, Jahn R, Brunger AT (1998) Crystal structure of a SNARE complex
involved in synaptic exocytosis at 2.4 A resolution. *Nature* 395: 347-353
Tan GH, Liu YY, Wang L, Li K, Zhang ZQ, Li HF, Yang ZF, Li Y, Li D, Wu MY *et al* (2018)
PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by regulating synaptic
transmission in cerebellum. *Cell Res* 28: 90-110
Tang F, Fan J, Zhang X, Zou Z, Xiao D, Li X (2022) The Role of Vti1a in Biological Functions
and Its Possible Role in Nervous System Disorders. *Front Mol Neurosci* 15: 918664
Tartour K, Appourchaux R, Gaillard J, Nguyen X-N, Durand Sp, Turpin J, Beaumont E, Roch E,
Berger G, Mahieux R *et al* (2014) IFITM proteins are incorporated onto HIV-1 virion particles
and negatively imprint their infectivity. *Retrovirology* 11: 103
Valente P, Castroflorio E, Rossi P, Fadda M, Sterlini B, Cervigni RI, Prestigio C, Giovedì S,
Onofri F, Mura E *et al* (2016) PRRT2 Is a Key Component of the Ca2+-Dependent
Neurotransmitter Release Machinery. *Cell Reports* 15: 117-131
Varadi M, Bertoni D, Magana P, Paramval U, Pidruchna I, Radhakrishnan M, Tsenkov M, Nair S,
Mirdita M, Yeo J *et al* (2024) AlphaFold Protein Structure Database in 2024: providing structure
coverage for over 214 million protein sequences. *Nucleic Acids Res* 52: D368-D375
Veit M, Sollner TH, Rothman JE (1996) Multiple palmitoylation of synaptotagmin and the t-
SNARE SNAP-25. *FEBS Lett* 385: 119-123
Wang Y, Pan Q, Ding S, Wang Z, Yu J, Finzi A, Liu S-L, Liang C (2017) The V3 Loop of HIV-1
Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. *Journal of*
Virology 91: e02441-02416-02417
Wesolowski J, Paumet F (2010) SNARE motif: a common motif used by pathogens to
manipulate membrane fusion. *Virulence* 1: 319-324

Wojnacki J, Nola S, Bun P, Cholley B, Filippini F, Presse MT, Lipecka J, Lam SM, N'Guyen J,
Simon A *et al* (2021) Role of VAMP7-dependent secretion of reticulon 3 in neurite growth. *Cell*
Reports 35: 109006
Xiao W, Poirier MA, Bennett MK, Shin YK (2001) The neuronal t-SNARE complex is a parallel
four-helix bundle. *Nat Struct Biol* 8: 308-311
Yount JS, Karssemeijer RA, Hang HC (2012) S-palmitoylation and ubiquitination differentially
regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza
virus. *J Biol Chem* 287: 19631-19641
Yount JS, Moltedo B, Yang Y-Y, Charron G, Moran TM, López CB, Hang HC (2010)
Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. *Nat*
Chem Biol 6: 610-614
Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, Zheng Y-M, Freed EO, Liang C, Chen
BK *et al* (2015) IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope
Glycoprotein. *Cell Reports* 13: 1-13
Zhang Y, Skolnick J (2005) TM-align: a protein structure alignment algorithm based on the TM-
score. *Nucleic Acids Res* 33: 2302-2309

885
886 **Figure Legends**
887
Figure 1: CD225 proteins contain a motif resembling an R-SNARE motif.
(A) A selection of SNARE proteins from yeast and mammals were aligned with proteins with
SNARE-like motifs, and a 53-residue stretch of sequence is shown. Proteins are grouped by Q-
SNARE, R-SNARE, or R-SNARE-like, and CD225 proteins are labeled as a subset of the R-
SNARE-like proteins. Residues in red text are the central polar arginine or glutamine residues
characteristic of canonical SNARE proteins and are labeled as the central "0" layer. Surrounding
heptad repeats of hydrophobic residues are labeled from "-7" to "+8" in relation to the "0" layer,
and sites highlighted in yellow correspond to hydrophobic residues. Underlined residues are
those found in PRRT2, which when mutated, are associated with neurological dysfunction. (B)
Left: HEK293T cells were co-transfected with SNAP25-HA and either PRRT2-FLAG (WT,
R295Q, G305W, or A320V) or Empty Vector. SDS-PAGE and immunoblotting were performed
with anti-HA and anti-FLAG in whole cell lysates. Anti-actin was used as loading control. Right:
From co-transfected cells, SNAP25-HA was immunoprecipitated with anti-HA followed by
SDS-PAGE and immunoblotting with anti-HA and anti-FLAG. Immunoglobulin chain was used
as loading control. Numbers and tick marks left of blots indicate position and size (in
kilodaltons) of protein standard in ladder. The FLAG/HA ratio was calculated for the indicated
lanes and shown as mean and standard error (normalized relative to WT, which was set to
100%). Differences that were statistically significant from WT as determined by one-way
ANOVA are indicated by (*). Exact p values are as follows (from left to right): $p < 0.0001$, $p <$
0.0001, $p < 0.0001$. Immunoblots were performed independently three times (biological
replicates), and a representative example is shown. Sc; Saccharomyces cerevisiae. Ig;
immunoglobulin. IP; immunoprecipitation. EV; empty vector. WT; wild-type.
910
911 **Figure 2: IFITM3 contains an R-SNARE-like motif and interacts with ectopic endosomal**
912 **Q-SNARE STX7.**
913 (A) Human endosomal SNARE proteins were aligned with aligned with human IFITM proteins,
914 and a 53-residue stretch of sequence is shown. Residues in red text are the central polar arginine

or glutamine residues characteristic of canonical SNARE proteins and are labeled as the central "0" layer. Surrounding heptad repeats of hydrophobic residues are labeled from "-7" to "+8" in relation to the "0" layer, and sites highlighted in yellow correspond to hydrophobic residues. Black underlined residues in IFITM3 which were mutated for functional experiments. Green underlined residues in IFITM3 correspond to the previously described amphipathic alpha helix. (B) HEK293T cells were transfected with IFITM3-FLAG (WT, F75/78A, R85Q, or G95L) and, 48 hours later, challenged with IAV (A/PR/8/34 (PR8), H1N1) at a multiplicity of infection of 0.10. 18 hours post-infection, cells were fixed, permeabilized, immunostained with anti-FLAG and anti-NP, and analyzed by flow cytometry. The percentage of NP+ cells was measured as a fraction of FLAG+ cells and shown as mean and standard error (normalized relative to Empty Vector, which was set to 100%). Infections were performed independently three times (biological replicates). Differences that were statistically significant from WT as determined by one-way ANOVA are indicated by (*). Exact p values are as follows (from left to right): $p < 0.0001$, $p < 0.0001$, $p < 0.0001$. (C) Structural prediction of the R-SNARE-like motif of IFITM3 was performed with Alphafold and FATCAT. Residues 55-113 of IFITM3 were modeled against a template of the R-SNARE motif of VAMP8 which was previously crystallized as part of the STX7-STX8-Vti1b-VAMP8 trans-SNARE complex (PDB: 1GL2). (D) Left: HEK293T cells were co-transfected with IFITM3-FLAG or Empty Vector and a construct encoding a single SNARE protein: STX7-HA, STX8-HA, Vti1b-HA, VAMP8-HA, or VAMP7-myc. SDS-PAGE and immunoblotting were performed with anti-HA, anti-myc, and anti-FLAG in whole cell lysates. Anti-actin was used as loading control. Right: From co-transfected cells, IFITM3-FLAG was immunoprecipitated with anti-FLAG followed by SDS-PAGE and immunoblotting with anti-HA, anti-myc, and anti-FLAG. Heavy chain immunoglobulin chain was used as loading control. Co-transfection of Empty Vector and STX7-HA was used as a negative control for immunoprecipitation. (E) Left: HEK293T cells were co-transfected with STX7-HA and either IFITM3-FLAG (WT, F75/78A, or R85Q) or Empty Vector. SDS-PAGE and immunoblotting were performed with anti-HA and anti-FLAG in whole cell lysates. Anti-actin was used as loading control. Right: From co-transfected cells, IFITM3-FLAG was immunoprecipitated with anti-FLAG followed by SDS-PAGE and immunoblotting with anti-FLAG and anti-HA. Light chain immunoglobulin was used as loading control. Co-transfection of Empty Vector and STX7-HA was used as a negative control for immunoprecipitation. The HA/FLAG ratio was calculated for the indicated lanes and shown as mean and standard error (normalized relative to WT, which was set to 100%). Differences that were statistically significant from WT as determined by one-way ANOVA are indicated by (*). Exact p values are as follows (from left to right): $p < 0.0001$, $p < 0.0001$. Numbers and tick marks left of blots indicate position and size (in kilodaltons) of protein standard in ladder. Immunoblots were performed independently three times, and a representative example is shown. IAV; Influenza A virus. Ig; immunoglobulin. IP; immunoprecipitation. EV; Empty Vector. WT; wild-type.

Figure 3: IFITM3 interacts with endosomal Q-SNAREs in a G95-dependent manner
(A) Top: HEK293T cells were co-transfected with STX8-HA, STX7-HA, or Vti1b-HA and either Empty Vector or IFITM3-FLAG (WT, F75/78A, or G95L). SDS-PAGE and immunoblotting were performed with anti-HA and anti-FLAG in whole cell lysates. Anti-tubulin was used as loading control. Bottom: from co-transfected cells, STX8-HA, STX7-HA, or Vti1b-HA were immunoprecipitated with anti-HA followed by SDS-PAGE and immunoblotting with anti-HA and anti-FLAG. Heavy chain immunoglobulin was used as loading control. Co-transfection of

Empty Vector and STX8-HA was used as a negative control for immunoprecipitation. The
FLAG/HA ratio was calculated for the indicated lanes and shown as mean and standard error
(normalized relative to WT with STX7-HA, which was set to 100%). Differences that were
statistically significant from WT with STX7-HA as determined by one-way ANOVA are
indicated by (*). Exact p values are as follows (from left to right): $p < 0.0001$, $p < 0.0001$, $p <$
0.0001, $p < 0.0001$, $p < 0.0001$. Numbers and tick marks left of blots indicate position and size
(in kilodaltons) of protein standard in ladder. Immunoblots were performed independently three
times, and a representative example is shown. (B) HEK293T cells stably expressing Empty
Vector, IFITM3 WT-FLAG, or IFITM3 G95L-FLAG were transfected with STX7-GFP, fixed,
immunostained with anti-FLAG, and analyzed by confocal immunofluorescence microscopy.
Colocalization was measured between FLAG and STX7-GFP by calculating the Pearson's
Correlation Coefficient using Fiji software. Coefficients were calculated from medial Z-slices
from three fields of view containing 5-15 cells per condition and presented as means and
standard error. Scale bar = 15 microns. Ig; immunoglobulin. IP; immunoprecipitation. EV;
Empty Vector. WT; wild-type. PCC; Pearson's Correlation Coefficient.
976
Figure 4: Endogenous IFITM3 interacts with endosomal Q-SNAREs and R-SNAREs via an
R-SNARE-like motif.
(A) Left: HeLa cells (WT or *IFITM3* KO) were transfected with STX7-HA. SDS-PAGE and
immunoblotting were performed with anti-HA and anti-IFITM3 in whole cell lysates. Anti-actin
was used as loading control. Right: STX7-HA was immunoprecipitated with anti-HA antibody
followed by SDS-PAGE and immunoblotting with anti-HA and anti-IFITM3. Heavy chain
immunoglobulin was used as loading control. An isotype matched antibody was used as a control
for immunoprecipitation. (B) Endogenous STX8 was immunoprecipitated from HeLa (WT or
IFITM3 KO) with anti-STX8 followed by SDS-PAGE and immunoblotting with anti-STX8 and
anti-IFITM3. Heavy chain immunoglobulin was used as loading control. An isotype matched
antibody was used as a control for immunoprecipitation. The (#) symbol denotes the presence of
light chain immunoglobulin. (C) Endogenous Vti1b was immunoprecipitated from HeLa (WT or
IFITM3 KO) with anti-Vti1b followed by SDS-PAGE and immunoblotting with anti-Vti1b and
anti-IFITM3. Light chain immunoglobulin was used as loading control. (D) Endogenous VAMP8
was immunoprecipitated from HeLa (WT or *IFITM3* KO) with anti-VAMP8 followed by SDS-
PAGE and immunoblotting with anti-VAMP8 and anti- IFITM3. Light chain immunoglobulin
was used as loading control. (E) Endogenous VAMP7 was immunoprecipitated from HeLa (WT
or *IFITM3* KO) with anti-VAMP7 followed by SDS-PAGE and immunoblotting with anti-
VAMP7 and anti-IFITM3. Two forms of VAMP7 were detected following immunoprecipitation:
one form of approximately 25 kD and another of approximately 15 kD (Wojnacki *et al*, 2021).
Light chain immunoglobulin was used as loading control. (F) Left: Recombinant STX7 and
recombinant IFITM3 (WT, F75/78A, or G95L) were mixed together in vitro and reaction inputs
were visualized by SDS-PAGE and immunoblotting with anti-STX7 and anti-IFITM3. Right:
recombinant STX7 was immunoprecipitated with anti-STX7 followed by SDS-PAGE and
immunoblotting with anti-STX7 and anti-IFITM3. Heavy chain immunoglobulin was used as
loading control. Numbers and tick marks left of blots indicate position and size (in kilodaltons)
of protein standard in ladder. Immunoblots were performed independently two times and a
representative example is shown. Ig; immunoglobulin. IP; immunoprecipitation. KO; knockout.
WT; wild-type. r; recombinant.
1006

Figure 5: IFITM3 inhibits the interaction between STX7/8 and VAMP8.
(A) HEK293T cells stably expressing Empty Vector, IFITM3 WT-FLAG, or IFITM3 G95L-FLAG were co-transfected with STX7-HA and VAMP8-Myc. Whole cell lysates were subjected to SDS-PAGE and immunoblotting with anti-HA, anti-FLAG, and anti-Myc. Actin was used as a loading control. Right: STX7-HA was immunoprecipitated with anti-HA followed by SDS-PAGE and immunoblotting with anti-HA, anti-FLAG, and anti-Myc. The Myc/HA ratio was calculated for the indicated lanes and shown as mean and standard error (normalized relative to Empty Vector, which was set to 100%). Differences that were statistically significant from Empty Vector as determined by one-way ANOVA are indicated by (*). Exact p values are as follows (from left to right): $p = 0.0016$, $p = 0.4318$. (B) HEK293T cells stably expressing Empty Vector, IFITM3 WT-FLAG, or IFITM3 G95L-FLAG were transfected with STX7-GFP and VAMP8-mCherry, fixed, and analyzed by confocal immunofluorescence microscopy. Colocalization was measured between STX7-GFP and VAMP8-mCherry by calculating the Pearson's Correlation Coefficient using Fiji software. Coefficients were calculated from medial Z-slices from three fields of view containing 5-15 cells per condition and presented as means and standard error. Scale bar = 15 microns. (C) HEK293T cells stably expressing Empty Vector, IFITM3 WT-FLAG, or IFITM3 G95L-FLAG were inoculated with IAV (+) or medium (-) for 18 hours and subjected to whole cell lysis. Endogenous STX8 was immunoprecipitated with anti-STX8 followed by SDS-PAGE and immunoblotting with anti-STX8, anti-FLAG, anti-VAMP8, and anti-VAMP7. The VAMP8/STX8 and VAMP7/STX8 ratios were calculated for the indicated lanes and shown as mean and standard error (normalized relative to No Virus Empty Vector, which was set to 100%). Differences that were statistically significant from No Virus Empty Vector as determined by one-way ANOVA are indicated by (*). Exact p values are as follows (from left to right, top to bottom): $p = 0.0007$, $p = 0.6986$, $p = 0.0093$, $p = 0.4523$, $p < 0.0001$, $p = 0.7960$. (D) Endogenous STX8 was immunoprecipitated from HeLa cells (WT or *IFITM3* KO) with anti-STX8 followed by SDS-PAGE and immunoblotting with anti-STX8, anti-IFITM3, and anti-VAMP8. Light chain immunoglobulin was used as loading control. An isotype matched antibody was used as a control for immunoprecipitation. The VAMP8/STX8 ratio was calculated for the indicated lanes and shown as mean and standard error (normalized relative to WT, which was set to 100%). Differences that were statistically significant from WT as determined by student's T test are indicated by (*). Exact p value: $p = 0.0009$. Numbers and tick marks left of blots indicate position and size (in kilodaltons) of protein standard in ladder. The (#) symbol denotes the presence of light chain immunoglobulin. Immunoblots were performed independently three times, and a representative example is shown. Ig; immunoglobulin. IP; immunoprecipitation. EV; Empty Vector. WT; wild-type. PCC; Pearson's Correlation Coefficient.

Figure 6: IFITM3 inhibits assembly of late endosome homotypic fusion machinery and promotes the delivery of endosomal cargo to lysosomes. (A) HEK293T stably expressing Empty Vector, IFITM3 WT-FLAG, or IFITM3 G95L-FLAG were co-transfected with STX7-HA, STX8-HA, Vti1b-HA, and VAMP8-Myc. Following whole cell lysis, samples were either boiled at 100°C (+) or not (-). SDS-PAGE and immunoblotting was performed with anti-Myc and anti-FLAG. Actin was used as loading control. Numbers and tick marks left of blots indicate position and size (in kilodaltons) of protein standard in ladder. Immunoblots were performed independently twice, and a representative example is shown. (B) HEK293T cells stably expressing Empty Vector, IFITM3 WT-FLAG, or IFITM3 G95L-FLAG were pulsed with

Dextran Alexa Fluor 488 for 2 hrs followed by addition of Magic Red for 5 mins. Living cells
were then analyzed immediately by confocal immunofluorescence microscopy. Colocalization
between Dextran and Magic Red was measured by calculating the Pearson's Correlation
Coefficient using Fiji software. Coefficients were calculated from medial Z-slices from three
fields of view containing 5-15 cells per condition and presented as means and standard error.
Scale bar = 15 microns. PCC; Pearson's Correlation Coefficient.
1059
Figure 7: IFITM3 traffics incoming IAV to lysosomes in a G95-dependent manner.
(A) HEK293T cells stably expressing Empty Vector, IFITM3 WT-FLAG, or IFITM3 G95L-
FLAG inoculated with IAV at a multiplicity of infection of 1 and incubated on ice for 40
minutes. Cells were washed, fresh medium containing Lysotracker Deep Red (50 nM) was
added, and cells were placed at 37°C for 4 hours. Four hours later, cells were fixed and
immunostained with anti-NP antibody and Hoechst and analyzed by confocal
immunofluorescence microscopy. Mock-inoculated (PBS) Empty Vector cells were used as a
negative control. Scale bar = 15 microns. Medial Z-slices representative of each condition are
shown. (B) The percentage of NP+ nuclei was quantified in Empty Vector, IFITM3 WT-FLAG,
or IFITM3 G95L-FLAG cells. Symbols represent fields of view containing approximately 15-30
total cells and mean percentage plus standard error is shown. Differences that were statistically
significant between the indicated conditions as determined by one-way ANOVA are indicated by
(*). Exact p values are as follows (from left to right): $p < 0.0001$, $p = 0.0028$. (C) The Corrected
Total Cell Fluorescence (CTCF) intensity of Lysotracker staining was quantified in Empty
Vector, IFITM3 WT-FLAG, or IFITM3 G95L-FLAG cells. Symbols represent fields of view
containing approximately 15-30 total cells and mean CTCF intensity plus standard error is
shown. Differences that were statistically significant between the indicated conditions as
determined by one-way ANOVA are indicated by (*). Exact p values are as follows (from left to
right): $p = 0.0005$, $p = 0.0001$. (D) Examination of NP signal in relation to Lysotracker staining
in HEK293T stabling expressing IFITM3 WT-FLAG or IFITM3 G95L-FLAG. White boxes
indicate fields of view selected for detailed analysis. Right: detailed view of three different Z
slices from confocal stack. White boxes indicate fields of view selected for further detailed
analysis. White arrows indicate bright NP puncta that colocalize with Lysotracker or which
tightly appose a Lysotracker+ compartment. Colocalization between NP and Lysotracker was
measured by calculating the Pearson's Correlation Coefficient using Fiji software. Coefficients
were calculated from medial Z-slices from three fields of view containing 5-15 cells per
condition and presented as means plus standard deviation. Scale bar = 15 microns. EV; Empty
Vector. WT; wild-type. hpi; hours post-inoculation. CTCF; Corrected Total Cell Fluorescence.
PCC; Pearson's Correlation Coefficient.
1089
1090 **Figure 8: A model of inhibition of homotypic late endosome fusion by IFITM3.**
1091 IFITM3 selectively regulates the trans-SNARE assembly driving late endosome-late endosome
1092 fusion (STX7-STX8-Vti1b-VAMP8), while enabling late endosome-lysosome fusion. As a result,
1093 endocytic cargos (including viruses) are more efficiently trafficked to lysosomes in IFITM3-
1094 expressing cells. LE; late endosome. Lys; lysosome.
1095
1096 **Expanded View Figure Legends**
1097

Figure EV1: An R-SNARE-like motif is semi-conserved among human CD225 family members.

(A) Human CD225 proteins were aligned and trimmed to a 53-residue stretch of sequence covering the SNARE motif. Proteins are grouped by whether they contain an arginine at the central "0" layer (R-SNARE-like) or not. Surrounding heptad repeats of hydrophobic residues are labeled from "-7" to "+8" in relation to the "0" layer, and sites highlighted in yellow correspond to hydrophobic residues. (B) Left: HEK293T cells were co-transfected with STX1A-HA and either PRRT2-FLAG (WT, R295Q, G305W, or A320V) or Empty Vector. SDS-PAGE and immunoblotting were performed with anti-HA and anti-FLAG in whole cell lysates. Anti-actin was used as loading control. Right: From co-transfected cells, STX1A-HA was immunoprecipitated with anti-HA followed by SDS-PAGE and immunoblotting with anti-HA and anti-FLAG. Immunoglobulin chain was used as loading control. (C) Left: HEK293T cells were co-transfected with STX4-HA and either TUSC5-FLAG (WT or G141W) or Empty Vector. SDS-PAGE and immunoblotting were performed with anti-HA and anti-FLAG in whole cell lysates. Anti-actin was used as loading control. Right: From co-transfected cells, TUSC5-FLAG was immunoprecipitated with anti-FLAG followed by SDS-PAGE and immunoblotting with anti-HA and anti-FLAG. Light chain immunoglobulin chain was used as loading control. The HA/FLAG ratio was calculated for the indicated lanes and shown as mean and standard error (normalized relative to WT, which was set to 100%). Differences that were statistically significant from WT as determined by student's T test are indicated by (*). Exact p value: $p < 0.0001$. (D) From co-transfected cells, STX4-HA was immunoprecipitated with anti-HA followed by SDS-PAGE and immunoblotting with anti-FLAG and anti-HA. Light chain immunoglobulin was used as loading control. Numbers and tick marks left of blots indicate position and size (in kilodaltons) of protein standard in ladder. Immunoblots were performed independently three times, and a representative example is shown (except for (D), which was performed twice). Ig; immunoglobulin. IP; immunoprecipitation. EV; Empty Vector. WT; wild-type.

Figure EV2: IFITM3 contains a motif resembling the alpha helical R-SNARE motif of VAMP8

(A) The R-SNARE-like motif of IFITM3 and the R-SNARE motif of VAMP8 (53 residues each) were compared by predictive protein structure alignment and comparison algorithm TM-align. A TM score of 0.75847 was recorded, indicating that the two regions are likely to adopt the same alpha helical protein fold. (B) Structural prediction of the R-SNARE-like motif of IFITM3 was performed with Alphafold and FATCAT. Residues 55-113 of IFITM3 were modeled against a template of the R-SNARE motif of VAMP8 which was previously crystallized as part of the STX7-STX8-Vti1b-VAMP8 trans-SNARE complex (PDB: 1GL2). VAMP8 was then swapped with the predicted structure of IFITM3 and shown in relation to the coiled-coiled structure formed with STX7, STX8, and Vti1b. Top: the side chains of residues F75, F78, and R85 of IFITM3 are depicted in yellow and labeled. Bottom: alternative view of the side chains of F75, F78, and R85 of IFITM3. (C) Top: examination of the central polar "0" layer of the Q-SNAREs STX7, STX8, Vti1b in relation to the R85 residue in the predicted configuration of IFITM3. Bottom: examination of the central polar "0" layer of the STX7-STX8-Vti1b-VAMP8 complex (PDB: IGL2).

Figure EV3: IFITM3 interacts with the R-SNAREs VAMP8 and VAMP7

(A) Left: HEK293T cells were co-transfected with VAMP8-HA and IFITM3-FLAG (WT or
G95L). SDS-PAGE and immunoblotting were performed with anti-HA and anti-FLAG in whole
cell lysates. Anti-actin was used as loading control. Right: From co-transfected cells, VAMP8-
HA was immunoprecipitated with anti-HA followed by SDS-PAGE and immunoblotting with
anti-HA and anti-FLAG. Light chain immunoglobulin chain was used as loading control. The
FLAG/HA ratio was calculated for the indicated lanes and shown as mean and standard error
(normalized relative to WT, which was set to 100%). Differences that were statistically
significant from WT as determined by student's T test are indicated by (*). Exact *p* value: $p <$
0.0001. (B) Left: HEK293T cells were co-transfected with VAMP7-myc and IFITM3-FLAG
(WT or G95L). SDS-PAGE and immunoblotting were performed with anti-myc and anti-FLAG
in whole cell lysates. Anti-actin was used as loading control. Right: From co-transfected cells,
VAMP7-myc was immunoprecipitated with anti-myc followed by SDS-PAGE and
immunoblotting with anti-myc and anti-FLAG. Light chain immunoglobulin chain was used as
loading control. The FLAG/Myc ratio was calculated for the indicated lanes and shown as mean
and standard error (normalized relative to WT, which was set to 100%). Differences that were
statistically significant from WT as determined by student's T test are indicated by (*). Exact *p*
value: $p = 0.0023$. Numbers and tick marks left of blots indicate position and size (in kilodaltons)
of protein standard in ladder. Immunoblots were performed independently three times, and a
representative example is shown. Ig; immunoglobulin. IP; immunoprecipitation. WT; wild-type.

Figure EV4: IFITM3 does not impair the STX7/STX8 or STX7/Vti1b interactions
(A) HeLa cells (WT or *IFITM3* KO) were subjected to whole cell lysis, SDS-PAGE, and
immunoblotting with anti-IFITM2/3, anti-STX8, anti-Vti1b, anti-VAMP8, anti-VAMP7, and
anti-actin. Red and green arrows indicate IFITM3 and IFITM2, respectively, recognized by the
anti-IFITM2/3 antibody. (B) STX7-HA was transfected into HeLa (WT or *IFITM3* KO) and
immunoprecipitated with anti-HA followed by SDS-PAGE and immunoblotting with anti-HA,
anti-IFITM3, anti-STX8, and anti-Vti1b. Heavy chain immunoglobulin was used as loading
control. An isotype matched antibody was used as a control for immunoprecipitation. The (#)
symbol denotes the presence of light chain immunoglobulin. (C) Purified recombinant IFITM3
protein (WT, F75/78A, or G95L) of varying inputs (6, 12 or 18 µg) were subjected to SDS-
PAGE and visualized by Coomassie stain. (D) 20 ng of purified recombinant IFITM3 protein
(WT, F75/78A, or G95L) were subjected to SDS-PAGE and immunoblotting with anti-IFITM3.
(E) Recombinant STX7 of varying inputs (0.5, 1, or 2 µg) were subjected to SDS-PAGE and
visualized by Coomassie stain. (F) Recombinant STX7 was subjected to SDS-PAGE and
immunoblotting with anti-STX7. Numbers and tick marks left of blots indicate position and size
(in kilodaltons) of protein standard in ladder. Immunoblots were performed independently two
times and a representative example is shown (for (A) and (B)) or once (for (C), (D), (E), and
(F)). Ig; immunoglobulin. IP; immunoprecipitation. EV; Empty Vector. WT; wild-type. r;
recombinant.

Figure EV5: IFITM3 does not impair the STX7/VAMP7 interaction
(A) Size exclusion chromatography was performed on recombinant IFITM3 proteins (WT,
F75/78A, and G95L) and eluted fractions were analyzed by SDS-PAGE and Coomassie staining.
150 µg recombinant protein was loaded as input and fraction numbers correspond to mL volumes
eluted from column. (B) Left: HEK293T cells stably expressing Empty Vector, IFITM3 WT-
FLAG, or IFITM3 G95L-FLAG were co-transfected with STX7-HA and VAMP7-Myc. Whole

cell lysates were subjected to SDS-PAGE and immunoblotting with anti-HA, anti-FLAG, and
anti-Myc. Actin was used as a loading control. Right: STX7-HA was immunoprecipitated with
anti-HA followed by SDS-PAGE and immunoblotting with anti-HA, anti-FLAG, and anti-Myc.
The Myc/HA ratio was calculated for the indicated lanes and shown as mean and standard error
(normalized relative to Empty Vector, which was set to 100%). Differences that were statistically
significant from Empty Vector as determined by one-way ANOVA are indicated by (*). Exact p
values are as follows (from left to right): $p = 0.0099$, $p = 0.8782$. Numbers and tick marks left of
blots indicate position and size (in kilodaltons) of protein standard in ladder. Immunoblots were
performed independently three times, and a representative example is shown (except (A), which
was performed once). (C) HeLa (WT or *IFITM3* KO) were transfected with STX7-GFP and
VAMP8-mCherry and confocal immunofluorescence microscopy was performed. Colocalization
between STX7-GFP and VAMP8-mCherry was measured by calculating the Pearson's
Correlation Coefficient using Fiji software. Coefficients were calculated from medial Z-slices
from three fields of view containing 5-15 cells per condition and presented as means and
standard error. Scale bar = 15 microns. IP; immunoprecipitation. WT; wild-type. r; recombinant.
1205

A

	−7	−6		−5	−4		−3	−2		−1	0		+1	+2		+3	+4		+5	+6		+7	+8	

Syntaxin 1a, Syntaxin 4, Syntaxin 6, Syntaxin 7, Syntaxin 8, Vti1a, Vti1b, SNAP-25, Syn8P (Sc) — Q-SNARE

VAMP1, VAMP2, VAMP3, VAMP5, VAMP7, VAMP8, YKT6 — R-SNARE

Tomosyn, Amisyn — R-SNARE

IFITM1, IFITM2, IFITM3, TUSC5, PRRT2 — R-SNARE-like / CD225

B

SNAP25-HA
PRRT2-FLAG
EV   WT   R295Q G305W A320V

HA
FLAG
Actin

Whole Cell Lysates

SNAP25-HA
PRRT2-FLAG
EV   WT   R295Q G305W A320V

HA
FLAG

| | 100 | 29* ± 8 | 1* ± 1 | 2* ± 1 | FLAG / HA |

Ig
Light chain

Anti-HA IP

A

```
              -7 -6    -5 -4    -3 -2 -1  0 +1 +2 +3 +4   +5 +6   +7 +8
Syntaxin 7    IRQLEADIMDINEIFKDLGMMIEQGDVIDSIEANVENAEVHVQQANQQLSRA
Syntaxin 8    LDALSSIISRQKQMGQEIGNELDEQNEIIDDLANLVENTDEKLRNETRRVNMV
Vti1b         IERSHRIATETDQIGSEIIEELGEQRDQLERTKSRLVNTSENLSKSRKILRSM
VAMP8         VRNLQSEVEGVKNIMTQNVERILARGENLEHLRNKTEDLEATSEHFKTTSQKV
VAMP7         VMETQAQVDELKGIMVRNIDLVAQRGERLELLIDKTENLVDSSVTFKTTSRNL

IFITM1        SLFNTLFLNWCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALIL
IFITM2        SLFNTLFMNTCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALIL
IFITM3     55 SLFNTLFMNPCCLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALIL 113
```

B

IAV Infection (Relative to EV)

EV
WT
F75/78A
R85Q
G95L

C

VAMP8

IFITM3

Overlay

VAMP8 STX8 STX7
Vti1b

D

EV | IFITM3-FLAG

Whole Cell Lysates

STX7-HA, STX7-HA, STX8-HA, Vti1b-HA, VAMP8-HA, VAMP7-Myc

HA/Myc
FLAG
Actin

EV | IFITM3-FLAG

Anti-FLAG IP

HA/Myc
FLAG
Ig Heavy chain

E

STX7-HA

IFITM3-FLAG

EV | WT | F75A, F78A | R85Q

Whole Cell Lysates

FLAG
HA
Actin

STX7-HA

IFITM3-FLAG

EV | WT | F75A, F78A | R85Q

Anti-FLAG IP

FLAG
HA

HA / FLAG: 100 | 29* ± 4 | 37* ± 5

Ig Light chain

A

Whole Cell Lysates

	STX8-HA			STX7-HA			Vti1b-HA		
	EV	IFITM3-FLAG			IFITM3-FLAG			IFITM3-FLAG		
		WT	F75A, F78A	G95L	WT	F75A, F78A	G95L	WT	F75A, F78A	G95L

HA
FLAG
Tubulin

Anti-HA IP

	STX8-HA			STX7-HA			Vti1b-HA		
	EV	IFITM3-FLAG			IFITM3-FLAG			IFITM3-FLAG		
		WT	F75A, F78A	G95L	WT	F75A, F78A	G95L	WT	F75A, F78A	G95L

HA
FLAG

FLAG / HA: 12* ± 5   4* ± 2   1* ± 1   100   30* ± 5   16* ± 4

Ig Heavy chain

B

STX7-GFP

| Empty Vector | IFITM3-FLAG WT | IFITM3-FLAG G95L |

STX7-GFP

FLAG

Merge

STX7 / FLAG
PCC = 0.580 ± 0.066

STX7 / FLAG
PCC = 0.155 ± 0.065

A

STX7-HA
VAMP8-Myc

EV | IFITM3-FLAG
WT | G95L

Whole Cell Lysates

40 — HA
15 — FLAG
15 — Myc
40 — Actin

STX7-HA
VAMP8-Myc

EV | IFITM3-FLAG
WT | G95L

Anti-HA IP

40 — HA
15 — FLAG
15 — Myc

| 100 | 32* ± 5 | 114 ± 12 | Myc / HA |

B

STX7-GFP
VAMP8-mCherry

Empty Vector | IFITM3-FLAG WT | IFITM3-FLAG G95L

STX7-GFP

VAMP8-mCherry

Merge

STX7 / VAMP8
PCC = 0.690 ± 0.025

STX7 / VAMP8
PCC = 0.187 ± 0.070

STX7 / VAMP8
PCC = 0.483 ± 0.119

C

EV | IFITM3-FLAG
| WT | G95L

Virus | − | + | + | +

30 — STX8
15 — FLAG
15 — VAMP8

| 100 | 212* ± 17 | 119 ± 11 | 175* ± 11 | VAMP8 / STX8 |

25 — VAMP7

| 100 | 115 ± 7 | 203* ± 9 | 109 ± 7 | VAMP7 / STX8 |

Anti-STX8 IP

D

HeLa | WT | WT | IFITM3 KO

30 — STX8   #
15 — VAMP8

| 100 | 394* ± 34 | VAMP8 / STX8 |

25 — Ig Light chain

Isotype IP | Anti-STX8 IP

A

STX7-HA
STX8-HA
Vti1b-HA
VAMP8-Myc

	EV		IFITM3-FLAG			
			WT	WT	G95L	G95L
Boil	−	+	−	+	−	+

140 —   Myc

15 —   Myc (monomer)

15 —   FLAG

40 —   Actin

Whole Cell Lysates

B

Dextran Alexa 488
Magic Red Cathepsin

Empty Vector	IFITM3-FLAG WT	IFITM3-FLAG G95L

Dextran

Magic Red

Merge

| Dextran / Magic Red PCC = 0.277 -/+ 0.045 | Dextran / Magic Red PCC = 0.587 -/+ 0.110 | Dextran / Magic Red PCC = 0.260 -/+ 0.095 |

NP / Lyso PCC = 0.023 -/+ 0.011

NP / Lyso PCC = 0.389 -/+ 0.104